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INVESTIGATING THE UNIQUE REACTIVITY OF NOVEL HX (X=Cl, 
Br) REAGENTS WITH ALKENES AND ALKYNES 
 
Rene E. Ebule 
 
November 16th, 2018 
 
The addition of hydrogen halides to carbon-carbon unsaturated systems is a classic 
synthetic transformation that gives rise to a variety of halogenated products as well as 
building blocks.1 The different routes to achieve hydrohalogenation make use of the 
hydrogen halides either in the gaseous form2 or in solution3, or their surrogates4. Only 
second to dihalogens, hydrogen halides are the most atom efficient source of 
halogenation. However, hydrogen halides are reactive gases at ambient temperature, 
posing a major challenge in their application. Handling gaseous hydrogen halide 
reagents requires expert knowledge and specialized equipment. We have investigated 
the formulation of environmentally benign organic aprotic hydrogen halide solutions to 
address this challenge. The properties of these formulations have been investigated in 
reactions with unsaturated systems.  
Given that hydrogen bonding may play a role in the formation of stable HX solutions, we 
sought to screen and investigate various solvents with strong hydrogen bonding 
capabilities that do not adversely jeopardize the intrinsic properties the HX molecules. 
The few commercially available aprotic HX-solutions have low concentrations of HX and 
vi 
 
therefore offer few synthetic advantages.5 The formulation of stable HX solutions with 
higher concentrations and better reactivity in hydrohalogenation was our goal.  
Inspired by Laurence et al’s concept of hydrogen bond basicity6 and their classification of 
organic molecules based on their basicity (pKBHX scale), we found that 1,3-dimethyl-
3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) formed a stable complex with HF 
molecules. Our newly formulated solution of hydrogen fluoride in DMPU has exhibited 
higher reactivity than its predecessors in a wide scope of transformations.7 We are 
pleased to report novel DMPU solutions of HCl and HBr. The advantages of these 
solutions are their relatively higher HX concentrations (12.6 M HCl and 10 M HBr) and 
bench stable over long periods of time compared to the commercially available organic 
solutions. Another unique quality of these solutions is their compatibility with water 
and/or base-sensitive reactions. In addition, DMPU is non-nucleophilic, so it won’t 
compete with halides in nucleophilic reactions. These new organic-based solutions of 
hydrogen halides have been applied in a metal-free hydrobromination of alkynes8 and a 
homogenous gold-catalyzed hydrochlorination of alkynes9. In addition, the combination 
of our new HCl reagent (HCl/DMPU) with sulfoxides forms a unique chlorothiolation 
system for alkenes with high regioselectivity.10 Under mild and transition-metal-free 
conditions, dimethylsulfoxide (DMSO) undergoes a one-carbon homologation to afford 4-
chloropiperidines from homoallylic amines via a Pummerer fragmentation mechanism. 
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1. INTRODUCTION  
 
1.1. Literature background for halogenation  
The elements of group VIIA of the periodic table are known as the halogens. They 
include fluorine (F), chlorine (Cl), bromine (Br), iodine (I) and astatine (At). The 
incorporation of these elements into compounds is also typically known as halogenation. 
Halogenation is a highly desirable process because it drastically modifies the physical 
and chemical properties of compounds and materials. Also, introducing halogens into 
molecules does not only provide functional handles due to the polar nature of the newly 
formed bonds, but also more avenues for molecular complexity via nucleophilic 
substitution11, radical12 or coupling13 reactions.  For example, the electronic properties of 
materials have been tuned or drastically modified by halogen incorporation. The 
resulting electronic or semiconductor materials are high yielding and have more stable 
active layers14. In the energy sector where natural gas has become an important source 
of energy feedstock in the later part of the 20th century, the relative inertness of natural 
gas makes it challenging for converting it to valuable products. One solution to this 
challenge has been to incorporate halogens into natural gas. In the pharmaceutical 
industry, fluorinated compounds make up at least 25% of all pharmaceuticals15 while 
chlorinated compounds are estimated at over 50% of all industrial chemicals and 
polymers16. 20% of pharmaceuticals and about 30% of agrochemicals are chlorine 
containing compounds17. Key chlorinated building blocks have experienced growth from 
18 Mtons in the mid-1960s to 75 Mtons in the recent years. The chlorine tree18 (Figure 1) 
exemplifies the use of chlorine in the manufacture of a vast range of products. 
Bromination on the other hand, is a very important transformation in a vast number of 
  
2 
organic syntheses19. This has led to constant innovation in brominating reagents20. 
Compounds of bromine also have extensive applications as fire retardants and drilling 
fluids which constitute about 0.8 Mtons of brominated building blocks per year21.  
As evidenced by the large number of halogenated pharmaceuticals, agrochemicals and 
functional materials, the syntheses of new halogenated materials with diverse 
applications has arisen. This prevalence has resulted to extensive reports of novel 
halogenation techniques with the past few decades17, 22. Despite the extensive study of 
the chemistry of halogens and halogenated compounds, environmentally friendly 
technologies of incorporating halogens into daily consumer products are still sought.  
Figure 1.  Chlorine tree highlighting the range of chlorinated products 
 
 
Chemists are therefore constantly challenged to provide novel reagents, processes and 
methodologies to incorporate halogens into diverse compounds in an efficient and 
  
3 
environmentally safe fashion. Despite their excellent atom economy, the use of 
molecular dihalogens is limited due to their extreme reactivities, toxicity and difficulties in 
handling the gases. Safer alternative reagents such as the N-halo reagents have been 
developed to replace elemental halogens in electrophilic halogenation processes. Their 
poor atom economy and production of stoichiometric amounts of amide by-products 
makes them unsuitable for large-scale processes. The halogenation reagents developed 
to date fall under three classes; electrophilic,23 radical and nucleophilic halogenating 
reagents (Table 1). Of these, the electrophilic halogenating reagents are predominant.  
Table 1. Various halogenating agents  
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Another diatomic halogen source are the hydrogen halides. Of these, hydrogen fluoride 
is very dangerous to human tissue causing severe burns, while hydrogen chloride gas or 
acid solution is a strong corrosive acid, and hydrogen bromide is very pungent fuming 
gas. The interhalogens or organic halogenated compounds are another source. Simple 
halide salts will be ideal nucleophilic halogenating source due to their relatively mild and 
inert nature and ease of handing. However, solubility issues diminish their application in 
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organic syntheses. Widely applicable nucleophilic halogenating reagents are still rare. 
The covalent halides are extensively utilized for nucleophilic halogenation. They are 
however not easy to work with because they easily hydrolyze when exposed to moisture. 
This research specifically addresses some of the above challenges by developing of 
new atom economical, stable, practical and environmentally benign hydrogen halide 
(bromide and chloride) reagents. These novel nucleophilic halogenating reagents will be 
explored for their application in halogenation reactions. 
1.2. Hydrohalogenation  
1.2.1 General  
The addition of hydrogen halides to alkenes and alkynes is the most common and atom 
economical method of preparing halogenated alkanes and alkenes respectively. The 
addition reactions may proceed via a couple of pathways; first is the initial formation of a 
carbocation by bonding of the proton of the hydrogen halide to one of the carbons of the 
unsaturated system followed by the halide nucleophilic attack onto the carbocation24. A 
second and closely related pathway involves an initial proton bonding followed by a 
simultaneous anion addition. This precludes a distinct carbocation formation24a, b, 25. A 
third involves a 2π + 2σ addition (syn- or cis-)26 (Figure 2). However, hydrogen halides 
are gases at ambient temperature. This also presents a challenge in their utility. 
Nonetheless, given their acceptable solubilities in organic solvents27, various 
concentrations of aqueous and organic solutions of HX are commercially available (0.01 
M to 12 M)28. The choice of the hydrogen halide source is important based on the nature 
of the reaction type. For example, reactions that are moisture sensitive will require a 
non-aqueous source while proton sensitive reactions will require non-protic solvents. 
Also, high temperature dependent reactions will require HX solutions that are have a 
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relatively higher heat capacity (the ethereal sources are very volatile). A worthwhile 
endeavor will be that which will provide an organic hydrogen halide source that will be 
tolerant over a wider range of reaction conditions, inexpensive and easy to make. We 
considered hydrogen bonding as the basis of our research to seek strong hydrogen 
bond acceptor compounds which will form stable complexes with HX molecules. 
Figure 2.  Pathways for HX addition across π-bonds of alkenes or alkynes 
 
Based on extensive worked reported by Abraham29 and Laurence6 whereby the 
hydrogen bond ability of H-bonded complexes between anionic H-bond acceptors 
(HBAs) and neutral H-bond donors (HBDs) in organic solvents were quantified, a 
comprehensive database of hydrogen-bond basicity (pKBHX) was established. On this 
database, a larger pKBHX value indicates higher hydrogen-bond basicity or a better 
hydrogen bond acceptor characteristic. (Figure 3) Caution must be taken to not assume 
there is a simple correlation between the relative hydrogen-bond strength or hydrogen-
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bond basicity with their basicity (pKaH). The correlation may only hold true for closely 
related compounds in a series. 




















































For example, pyridine (pKaH = 5.2) is a much stronger base than pyridine N-oxide (pKaH 
= 0.79), but pyridine (pKBHX = 1.86) is a weaker hydrogen bond acceptor than pyridine N-
oxide (pKBHX = 2.72). 
1.2.2 Hydrofluorination  
Hydrogen fluoride (HF) solutions have been made and foundto have great utility in 
installing fluorine in molecules, significantly transforming their properties. These 
fluorinated compounds are biologically active and find applications in pharmaceutical 
drugs15b(Figure 4). In functional materials, they are applied in ionic liquids30, fluorinated 
graphene or fluorine-containing polymers31, water-proofing and non-stick coatings, such 
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as Teflon. The commercially available sources of HF solutions such as pyridine.HF 
(Olah’s reagent) and triethylamine.HF though widely used still have some limitations in 
scope due to incompatibility with base sensitive substrates and in transition metal-
catalyzed reactions where coordination with the metal reduces their reactivity32. With the 
development of a non-protic, non-basic and highly concentrated source of HF by our 
group, we found a way of circumventing some of the mentioned drawbacks. 1,3-
dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) is a  non-basic and weakly 
coordinating (towards cationic metal) hydrogen bond acceptor that can form stable 
complexes through hydrogen bonding7 with HX molecules. 
Figure 4.  Examples of fluorine containing drugs 
 
1.2.3. Hydrochlorination  
Hydrogen chloride is a very common laboratory acid. It is a gas at room temperature that 
readily dissolves in water to be used for many chemical applications. It is used on an 
industrial scale for the purification of table salt, leather processing, removal of sulfur from 
petrol, hydraulic fracturing, gelatin production, in sanitation and for the synthesis of vinyl 
chloride; a monomer of plastic PVC (polyvinyl chloride). 
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The commercially available non-aqueous hydrogen chloride (HCl) solutions include HCl-
ether and HCl-alcohol formulations whose maximum acid concentrations are 6 M. Due to 
the vast application of HCl in industry as a chlorinating source, a more concentrated 
source will reduce solvent waste. HCl is used in the chemical industry to produce a large 
variety of organic chlorinated compounds including fertilizers, dyes and the 
hydrochloride salts commonly used for drugs (Figure 5). In the metal industry, 
hydrometallurgical processes use hydrogen chloride to enhance the separation 
coefficient of ores and in electroplating. In the electronics industry, hydrogen chloride is 
used in semiconductor fabrication for etching of native oxide, CVD reactor cleaning or 
moisture getter33 and materials industry in photographic, textile, and rubber products.  
Figure 5. Examples of chlorine-containing drugs 
 
1.2.4 Hydrobromination  
Hydrogen bromide (HBr) is an important bromine source for many organic and inorganic 
compounds34. The commercially available solutions of HBr are aqueous HBr (48 % w/w) 
or HBr in acetic acid (33 % w/w). The use of these solutions for brominating or 
hydrobromination often result in competing reactions between the bromide nucleophiles 
and solvent anions. An HBr/DMPU complex will provide another anhydrous source for 
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hydrogen bromide whose reactivity has not been explored before. Some examples of 
brominated natural products and drug molecules are given in Figure 6.  
Figure 6. Examples of bromine containing compounds 
 
                         
1.3. Research aims  
1.3.1. Aim 1: The controlled hydrobromination of unactivated alkynes and 
alkenes. 
Although several easy-to-handle HBr reagents are available commercially or have been 
recently made,4e none of them are good choices for general hydrobromination reactions 
due to scope limitations and competing reactions. Thus, we investigated synthesizing 
vinyl bromides and bromoalkanes from unactivated alkynes and alkenes using 
HBr/DMPU under metal-free and solvent-free conditions. HBr and DMPU form the room 
temperature-stable complex HBr/DMPU, providing a mild, effective and selective 
hydrobrominating reagent toward alkynes, alkenes and allenes.  
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1.3.2. Aim 2: A hydrogen-bond donor assisted Au-catalyzed 
hydrochlorination of unactivated alkynes. 
Synthesizing vinyl chlorides from unactivated alkenes using HCl/DMPU with 
homogenous gold (I) chloride in a hydrogen-bond donor solvent, hexafluoroisopropanol 
(HFIP) is a novel approach that we aimed to develop. This highly regioselective 
homogeneous gold(I)-catalyzed anti-hydrochlorination of unactivated alkynes was 
studied at ambient temperature. We sought to overcome the incompatibility between 
conventional cationic gold catalysts and chloride by using a hydrogen bonding activation 
of Au-Cl bond. This approach was evaluated for scalability, functional group tolerance, 
and air sensitivity. 
1.3.3. Aim 3: A metal-free chlorothiolation of alkenes.  
We used HCl/DMPU and mild and non-toxic DMSO as source of thiomethyl moiety and 
explored its utility for the synthesis of β-chloromethylsulfides from alkenes. A novel 
method for the chlorothiolation of alkenes using HCl and sulfoxides to achieve the 1,2-
difunctionalization of unactivated alkenes was investigated. The combination of our new 
HCl reagent (HCl/DMPU) with sulfoxides affords a unique chlorothiolation system. 
Alkene scope, gram scale and product applications was investigated.  
1.3.4. Aim 4: Synthesis of 4-chloropiperidines from homoallylic amines via 
an aza-Pummerer approach.  
We studied a substrate dependent variation of aim 3. Here, HCl/DMPU induced the 
formation of (thiomethyl)methyl carbenium ion from DMSO. Homoallylic amines reacted 
with the generated electrophile to afford 4-chloropiperidines in good yields. The 
applicability of the method was studied for both aromatic and aliphatic amines. The use 
of HCl/DMPU as both non-nucleophilic base and chloride source constitutes an 
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environmentally benign alternative for piperidine formation. The reaction scope, 




2. HBr/DMPU: THE FIRST APROTIC ORGANIC 
SOLUTION OF HYDROGEN BROMIDE  
 
2.1 Background 
Alkyl and alkenyl bromides are common substrates in a wide scope of transformations, 
including nucleophilic substitution reactions,35 metallation reactions36 and transition 
metal-catalyzed cross-coupling reactions.37 Highly efficient synthetic approaches toward 
organic halides are in high demand because of their crucial role in synthesis. 
Electrophilic addition of hydrogen halides to alkenes and alkynes provides a uniformed 
approach toward branched alkyl and alkenyl halides, and is a model reaction in most 
textbooks of organic chemistry.38 Compared with other approaches, including 
deoxyhalogenation,39 Hunsdiecker reaction,40 hydrometallation-electrophilic 
halogenation,41 olefin metathesis42 and transition metal-catalyzed hydrohalogenation,43 
the electrophilic addition of hydrogen halides is atom economical. However, to succeed 
in such transformation, handling gaseous hydrogen halides44 with special and expensive 
equipment45 is almost always required. While there may be other methods to achieving 
hydrobromination of alkynes and alkenes, these usually involve the use of less 
environmentally benign precursors,  conditions and low atom economy.46 Moreover, HBr 
addition to alkynes and akenes in solution also results in uncontrollable radical-chain 
additions that give the anti-Markovnikov products.5, 47 We herein report the first room 
temperature stable solution of HBr in a neutral aprotic organic solvent - DMPU that 
expands the utility of HBr. This complex yielded a mild, effective and selective 
hydrobrominating reagent toward alkynes, alkenes and allenes. HBr/DMPU could also 
14 
replace other less atom-economic halogenating reagents in the halo-Prins reaction and 
deoxy-bromination reactions.  
Of the commercially available HBr reagents or those recently made,4e none are a good 
choice for a more general hydrobromination reaction due to scope limitations. Acetic 
acid solution of HBr is capable of hydrobrominating unsaturated hydrocarbons, but 
selectivity between hydrohalogenation and undesired hydroacetoxylation is poor,24c, 48 
because of the weak, but still nucleophilic, acetate anion and the reduced nucleophilicity 
of halide anions in protic medium.24b, 49 In addition, the rearrangement of the intermediate 
carbocation is not uncommon.50 Triphenylphosphine hydrobromide is known as an 
alternative HBr source, but triphenylphosphine tends to further react with formed alkyl 
bromides to produce phosphonium salts.51 Kropp et al52 in a minireview, highlighted a 
few applications of HBr with the aforementioned challenges. In this regard, HBr solution 
in a neutral aprotic medium would be the optimal choice to prevent competitive 
solvolysis reaction and to achieve high reactivity. However, the excess reactivity of HBr 
toward ethers and esters excludes ethereal and ester solvents. Inspired by the concept 
of hydrogen bond basicity (pKBHX) that was first systematically summarized by 
Laurence,53 we previously succeeded in a new formulation of hydrogen fluoride, HF-
DMPU,54 which exhibits a higher reactivity than its predecessors55 in a wide scope of 
transformations. We hypothesized that DMPU could effectively form hydrogen bond 
complexes with HBr. In addition, DMPU is inert toward alkylation reactions, thus it should 
not compete with HBr.  
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2.2 Results and discussion 
We were pleased to find that, by passing HBr gas through DMPU, we obtained a 
solution of HBr/DMPU in the form of a room temperature-stable liquid (Table 2, entry 3) 
with a higher mass percentage compared to other HBr solutions. 
Table 2. Comparison of Different Formulation of Hydrogen Halide Solutions 
Entry Formulation Mole ratio (HX:solvent) pKBHX of stabilizer 
1 HBr/water, 48%[a] 0.21 0.65 
2 HBr/AcOH, 33%[a] 0.36 N/A 
3 HBr/DMPU, 58% 2.2 2.79 
[a] Commercially available. 
We tested the reactivity of HBr-DMPU in hydrohalogenation reactions. HBr-DMPU 
showed a high reactivity toward alkyne 2-1a. Under neat conditions, it completely 
converted 2-1a into the hydrobromination product 2-2a in 83% yield, without the 
formation of the 6-exo-trig cyclization product (eq 1).56 Gram-scale reaction gave the 
same product in 85% isolated yield (eq 1). A small amount of gem-dibromide, because 
of a two-fold hydrobromination, was observed after extended reaction times. HBr-DMPU 
eliminated the use of gaseous HBr,44b the competitive hydroacetoxylation reaction using 
HBr-HOAc48c and avoided using a catalyst.43a, 57 
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A wide scope of alkynes could react smoothly with HBr/DMPU under ambient conditions 
(Table 3).  
Table 3. Hydrobromination of Alkynes 
 
Homopropargyl ester 2-1b, amide 2-1c and imide 2-1d afforded the corresponding 3-
bromo-but-3-enyl ester 2-2b, amide 2-2c and imide 2-2d in 82%, 83 % and 80% yields 
respectively, without any ester cleavage. Hex-5-ynoic acid 2-1e and its nitrile 2-1f also 
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yielded products 2-2e and 2-2f in 78 % and 89% respectively. Phenylacetylene, 2-1h, 
yielded (1-bromovinyl)benzene and (2-bromovinyl)benzene in a 97:3 ratio with a 
combined 92 % yield.  With internal alkynes, 1-phenylpropyne 2-1i yielded a 3:2 mixture 
of α- and β-bromides 2-2i with exclusive Z-configuration. The exclusive formation of Z-
isomers (trans addition) indicated to us that this transformation follows an AdE3 
mechanism58 and the bromide concentration in the reaction medium is not low.50 
Hydrobromination of decyne 2-1j provided 2-2j in a similar yield. 2-1k and 2-1l yielded 
the corresponding hydrobromination product 2-2k and 2-2l in regioselective manner, 
albeit a lower selectivity for 2-2k. This probably due to the diminished steric difference 
between methyl and bromomethyl.58a, 59 The predorminant Z-isomer is inferred from a 
trans addition of HBr. We however, do not have experimental evidence of that. 
Diphenylacetylene (2-1m) yielded the Z-product in a modest 68 %. The unsymmetrical 
diaryl acetylene (2-1n) gave a 4.6:1 mixture of regioisomers. The reaction with 
derivatized amino acid (2-1o) and estrone (2-1p) also proceeded in 71 % and 95 % 
yields respectively, showing the wide applicability of this method. 
Alkenes are also suitable substrates for HBr/DMPU hydrobromination (Table 4). 
Allylbenzenes 2-3a to 2-3c and tridecene 2-3e afforded the corresponding Markovnikov 
hydrobromination products 2-4a, 2-4b, 2-4c and 2-4e in excellent yields. The reaction 
time of 2-3b should be limited to 1 hour, since prolonged reaction times caused the 
demethylation of 2-4b. Styrene 2-3d was completely hydrobrominated, without the 
formation of commonly observed polymers.60 Homoallyl amide 2-3f, imide 2-3g and 
ester 2-3h afforded the corresponding hydrobromination products in good yield and with 
functional group tolerance. 2-4f could be directly converted into azetidine 2-5 upon a 
treatment with sodium hydride in DMF (eq. 2). The hydrobromination of internal alkenes 
were partially successful. β-Methyl styrene 2-3i and cyclohexene could be 
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hydrobrominated in quantitative yield, but several substrates could not be effectively 
hydrobrominated. For example, hydrobromination of α-methyl styrene 2-3k could be only 
partially achieved, even after an extended reaction time or after adding extra loading of 
HBr/DMPU. The relative reactivity could be attributed to the highly conjugated system for 
the benzylic carbocation.  
Table 4. Hydrobromination of Alkenes 
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Hydrobromination of methyl cinnamate 2-3l and stilbene 2-3m was not successful due to 
their slow conversion, competition with undesired demethylation or easy loss of HBr 
during purification. 
 
Alkynes are known to be less reactive than alkenes in a wide scope of electrophilic 
addition reactions,61 because of the anticipated highly energetic vinyl cation 
intermediate.58a However, using HBr/DMPU, alkyne 2-1b showed a faster conversion 
than alkene 2-1m in both, parallel and competition experiments (Scheme 1).  
Scheme 1. Reactivity comparison 
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This inversed reactivity could be attributed to the high concentration of HBr in the 
reaction medium, signaling a reaction profile that is different from that in diluted reaction 
medium. 62  
Scheme 2. Other synthetic reactions using DMPU-HBr 
 
HBr/DMPU was shown to be very useful in other bromination reactions. For example, 
typical halogenating reagents employed in organic synthesis are gaseous hydrogen 
halides, metal halides (e.g. AlX3, InX3, NbX5, GaX3, FeX3, SnX4), sulfonyl halides, boron 
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halides, phosphorus halides or silicon halides (Scheme 2),63 which either require special 
handling or produce large amounts of side products after the reaction, and each 
transformation requires a different halogenating reagent. HBr/DMPU, on the other hand, 
provided a uniform solution to all these transformations. It could substitute niobium and 
gallium halides in the bromo-Prins reaction (Scheme 2a).  
It can also convert alkyl alcohols 2-7 into alkyl bromides 2-8, with comparable yields thus 
replacing the corrosive PBr3 (Scheme 2b).64  
Hydrobromination of allenoic ester 2-9a occurred with the regioselective protonation of 
the sp2-hybridized α-carbon, producing a β-vinylic cation that was further trapped by 
bromide to provide a vinyl bromide 2-9b in 54% yield (Scheme 2c).65 The reduced yield 
was primarily caused by cleavage of the benzyl group, since formation of benzyl bromide 
was observed on GC-MS. 
 
2.3 Conclusion 
In conclusion, HBr-DMPU is a good alternative to existing of hydrogen bromide 
solutions. Its advantages lie in the ease of handling, high HBr concentration, high 
reactivity towards the hydrobromination of alkenes and alkynes without competition 
reactions caused by rearrangement or solvolysis.  
2.4 Experimental 
2.4 1. General 
GC-MS analysis was performed on a Hewlett Packard Model 6890 GC interfaced to a 
Hewlett Packard Model 5973 mass selective detector (15 m x 0.25 mm capillary column, 
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HP-5MS). NMR spectra were recorded on 400 MHz instrument. The chemical shifts are 
reported in δ (ppm) values relative to CHCl3 (δ 7.26 ppm for 1H NMR), multiplicities are 
indicated by s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), h (hextet), m 
(multiplet) and br (broad). Coupling constants, J, are reported in Hertz. All air and/or 
moisture sensitive reactions were carried out under argon atmosphere. DMPU was 
received from commercial supplier and dried over molecular sieves. All other 
commercially available reagents and solvents were used without further purification. The 
products were purified using a CombiFlash system or a regular glass column 
chromatography. TLC was developed on Merck silica gel 60 F254 aluminum sheets. All 
NMR solvents were purchased from Cambridge Isotope Laboratories, Inc. Most products 
formed in this reaction have been reported in literature (references are found in the 
manuscript), hence we only used NMR to confirm their identities by comparison with the 
published spectra. 
2.4.2. Reagent preparation  
A general assembly is indicated below (Figure 7). All operations were conducted in well 
ventilated fume hoods. 
Figure 7. Set-up for the preparation of HBr/DMPU 
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An argon inlet, a pressure-equalizing dropping funnel and inlet of a P2O5 gas washing 
tower are attached onto a 500 mL of three-neck round-bottom flask. One joint of another 
two-neck round-bottom receiving flask is connected to the outlet of a gas-washing tower, 
another joint of the same flask is attached to a drying tube. 
After flushing the whole system by argon for 10 minutes, phosphorus pentoxide (500 g, 
1.8 mol) and a stirring bar are added to the three-neck flask, hydrobromic acid (100 mL, 
0.89 mol) is charged into a dripping funnel, and DMPU (10 mL, 82.7 mmol) and a tiny 
stirring bar are placed in the receiving flask. Both two flasks are cooled in ice-water 
bathes. The argon flow rate is maintained at 1 mL/min. 
Hydrobromic acid (48%, w/w) is gradually dropped onto phosphorus pentoxide at a rate 
of 1 drop per 10 second, and an extremely exothermic reaction ensues. During 
absorption of HBr, the colorless DMPU turns into a viscous yellowish liquid and the 
receiving flask weighed periodically until there is no further increase in weight. The final 
weight of the solution is measured, and concentration reported as % w/w (58 % w/w).  
The resulting HBr-DMPU solution is then pipetted into an argon-flushed glass vessel 
with PTFE-lined cap. This solution is fumes slightly but is relatively bench-stable for 
several months. 
2.4.3. General procedure for Hydrobromination of Alkenes and Alkynes 
To an argon-flushed 2-dram vial loaded with 0.3 mmol of alkene or alkyne, 0.15 mL of 
HBr-DMPU was added under stirring at room temperature. GC-MS and TLC monitored 
reaction progress. Once complete, the reaction mixture was quenched by adding 2 mL 
of saturated sodium bicarbonate solution and extracted by 2 mL of ethyl acetate over a 
vortex mixer for 3 times. To the combined extract, 1 gram of silica gel was added, and 
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the solvent was removed under a reduced pressure. The final product was purified by 
flash column chromatography using ethyl acetate-hexane eluent. 
2.4.4. General procedure for bromo-Prins cyclization reaction  
Homoallylic alcohol (43 µL, 0.5 mmol) and aldehyde (0.5 mmol) were dissolved in 0.5 
mL dichloromethane, then HBr-DMPU was added to the mixture and was stirred at room 
temperature. Upon completion, the reaction the mixture was quenched with cold water 
and the organic phase was extracted with chloroform. The organic phase was washed 
with aqueous sodium bicarbonate, and brine, dried over sodium sulfate and was 
concentrated to dryness in vacuum. The crude product purified by column 
chromatography with a 10:1 mixture of hexanes and EtOAc to afford the desired product. 
2.4.5. Product characterization  
 2-2a  
 
1H NMR (400 MHz, CDCl3) δ 7.30 (t, J = 7.5 Hz, 2H), 7.19 (d, J = 7.4 Hz, 3H), 5.58 (s, 
1H), 5.43 (s, 1H), 2.64 (t, J = 7.8 Hz, 2H), 2.46 (t, J = 7.4 Hz, 2H), 1.91 (p, J = 7.5 Hz, 






52.3 mg of Homopropargyl benzoate reacted with DMPU-HBr under standard conditions 
afforded 62.7 mg of 2c in 82% yield. 
1H NMR (400 MHz, CDCl3) δ 8.11 – 7.95 (m, 2H), 7.64 – 7.53 (m, 1H), 7.51 – 7.38 (m, 
2H), 5.80 – 5.65 (m, 1H), 5.54 (d, J = 1.7 Hz, 1H), 4.51 (t, J = 6.3 Hz, 2H), 2.89 (t, J = 
6.3 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 133.0, 133.1, 129.6, 129.4, 128.4, 119.1, 





44.7 mg of N-Toluenesulfonyl homopropargyl amide reacted with HBr-DMPU under 
standard conditions afforded 50.6 mg of 2d in 83% yield. 1H NMR (400 MHz, CDCl3) δ 
7.94 – 7.61 (m, 1H), 7.41 – 7.18 (m, 1H), 5.58 (s, 0H), 5.46 (s, 0H), 4.74 (s, 0H), 3.26 – 
3.02 (m, 1H), 2.55 (t, J = 6.3 Hz, 1H), 2.42 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 143.6, 
136.9, 129.8, 129.6, 127.0, 120.0, 41.3, 40.9. HR-MS (ESI): Exact Mass Calcd for 




59.8 mg of Homopropargyl phthalimide reacted with HBr-DMPU under standard 
conditions yielded 67.5 mg of 2e in 80% yield. 1H NMR (400 MHz, CDCl3) δ 7.84 (dd, J = 
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5.4, 3.1 Hz, 2H), 7.71 (dd, J = 5.5, 3.0 Hz, 2H), 5.61 (d, J = 1.6 Hz, 1H), 5.44 (d, J = 1.8 
Hz, 1H), 3.93 (t, J = 6.9 Hz, 2H), 2.84 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 




56.1 mg of 5-hexynoic acid reacted with HBr-DMPU under standard conditions afforded 
77.2 mg of 2f in 80% yield. 1H NMR (400 MHz, CDCl3) δ 7.26 (s, 1H), 5.66 – 5.56 (m, 
1H), 5.48 – 5.33 (m, 1H), 2.50 (t, J = 7.5 Hz, 2H), 2.39 (t, J = 7.4 Hz, 2H), 1.91 (p, J = 




46.6 mg of 5-cyanopentyne reacted with with HBr-DMPU under standard conditions 
afforded 67.8 mg of 2g in 78% yield. 1H NMR (400 MHz, CDCl3) δ = 5.70 (d, J=1.1, 1H), 
5.50 (s, 1H), 2.60 (t, J=6.9, 2H), 2.38 (ddd, J=7.0, 4.2, 1.3, 2H), 2.00 – 1.88 (m, 2H). 13C 





122 mg of non-8-yn-1-yl benzoate reacted with HBr-DMPU under standard conditions 
provided 144.7 mg of 2h in 89% yield.  1H NMR (400 MHz, CDCl3) δ = 8.03 (d, J=7.3, 
2H), 7.54 (t, J=7.4, 1H), 7.43 (t, J=7.6, 2H), 5.53 (s, 1H), 5.36 (s, 1H), 4.30 (t, J=6.6, 2H), 
2.39 (t, J=7.4, 2H), 1.81 – 1.69 (m, 2H), 1.60 – 1.18 (m, 14H). 13C NMR (100 MHz, 





32.9 µL of phenylacetylene reacted with HBr-DMPU under standard conditions provided 
168.4 mg of 2h in 92% yield. 1H NMR (400 MHz, CDCl3) δ = 7.58 (d, J=5.6, 2H), 7.33 
(m, 3H), 6.11 (d, J=1.9, 1H), 5.77 (d, J=1.9, 1H). 13C NMR (100 MHz, cdcl3) δ 138.5, 
133.8 129.1, 128.2, 127.3, 117.7. 
 
2-2i-α and 2-2i-β 
 
 
46.5 mg of 1-Phenyl prop-1-yne reacted with HBr-DMPU under standard conditions 
provided 72 mg of 2i in 90% yield.  1H NMR (400 MHz, CDCl3) δ 7.61 – 7.49 (m, 2H), 
7.39 – 7.27 (m, 3H), 6.74 (s, 0.42H for 2i-β), 6.29 (q, J = 6.6 Hz, 0.67H for 2i-α), 2.50 (d, 
J = 1.4 Hz, 1.4H for 2i-β), 1.96 (d, J = 6.6 Hz, 2.1H for 2i-α). 13C NMR (100 MHz, CDC3) 
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Reaction of 73.4 µL of 4-octyne reacted with HBr-DMPU under standard conditions 
afforded 85 mg of 2j in 89% yield. 1H NMR (700 MHz, CDCl3) δ = 5.61 (t, J=6.8, 1H), 
2.38 (t, J=7.2, 2H), 2.12 (q, J=7.1, 2H), 1.59 – 1.52 (m, 2H), 1.41 (dd, J=14.8, 7.4, 2H), 
0.89 (dt, J=25.6, 7.4, 6H). 13C NMR (176 MHz, CDCl3) δ 128.5, 128.2, 43.5, 33.3, 21.8, 




Reaction of 43.8µL mg of 1-bromo-2-butyne reacted with HBr-DMPU under standard 
conditions afforded 94.1 mg of 2k in 88% yield. 1H NMR (400 MHz, CDCl3) δ 5.97 (ddd, 
J=7.9, 4.6, 1.3, 1H), 4.04 (dd, J=7.8, 0.7, 2H), 2.39 – 2.30 (m, 3H). 13C NMR (100 MHz, 





Reaction of 82.6µL of ethylphenylpropiolate reacted with HBr-DMPU under at 70 oC to 
afford 94.4 mg of 2l in 74% yield. 1H NMR (400 MHz, CDCl3) δ = 7.69 – 7.55 (m, 2H), 
7.45 – 7.33 (m, 3H), 6.72 (s, 1H), 4.28 (q, J=7.1, 2H), 1.34 (t, J=7.2, 3H). 13C NMR (100 




Reaction of 35.6 mg of diphenylacetylene reacted with HBr-DMPU at 70 oC to afford 
35.2 mg of 2m in 68% yield. 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 7.8 Hz, 2H), 7.65 
(d, J = 7.8 Hz, 2H), 7.43 – 7.29 (m, 6H), 7.21 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 




Reaction of 98.1 mg of 1-fluoro-4-(phenylethynyl) benzene reacted with HBr-DMPU at 
70 oC to afford 103.9 mg of 2n in 75% yield.  1H NMR (400 MHz, CDCl3) δ 7.17 - 7.61 (m, 
4H), 7.43 – 7.30 (m, 3H), 7.16 (s, 1H), 7.11 - 7.04 (m, 2H).  13C NMR (100 MHz, CDCl3) δ 
131.1, 129.9, 129.5, 129.1, 128.8, 128.4, 128.2, 127.7, 115.3, 115.1. 19F NMR (376 MHz, 





Reaction of 54.7 mg of (S)-methyl 2-(hex-5-ynamido)-3-phenylpropanoate reacted with 
HBr-DMPU under standard conditions afforded 50.3 mg of 2o in 71% yield. 1H NMR 
(400 MHz, DMSO-d6) δ 12.63 (s, 1H), 8.18 (d, J=8.2, 1H), 7.36 – 6.96 (m, 5H), 5.60 (s, 
1H), 5.38 (d, J=1.7, 1H), 4.40 (td, J=10.0, 4.5, 1H), 3.04 (dd, J=13.8, 4.6, 1H), 2.80 (dd, 
J=13.8, 10.2, 1H), 2.51 – 2.46 (m, 2H), 2.26 (t, J=7.7, 2H), 2.04 (dd, J=11.6, 7.6, 2H), 
1.60 (dd, J=13.7, 6.4, 2H). 13C NMR (100 MHz, DMSO-d6) δ 173.7, 172.0, 138.2, 134.1, 




Reaction of 75.7 mg of (8R,9S,13S,14S)-3-(but-3-yn-1-yloxy)-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one reacted with 
HBr-DMPU under standard conditions to afford 87.3 mg of 2p in 95% yield. 1H NMR 
(400 MHz, CDCl3) δ 7.19 (d, J=8.6, 1H), 6.70 (dd, J=8.6, 2.2, 1H), 6.64 (s, 1H), 5.55 (s, 
1H), 5.38 (s, 1H), 3.93 (q, J=6.1, 2H), 2.89 (dd, J=10.8, 4.6, 2H), 2.54 – 1.91 (m, 10H), 
1.81 – 1.24 (m, 14H), 0.90 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 221.0, 157.1, 137.7, 
134.7, 131.8, 126.3, 116.4, 114.5, 112.1, 67.7, 52.8, 50.4, 48.0, 44.0, 41.3, 38.4, 35.9, 





Reaction of 23.8 mg allylbenzene with HBr-DMPU under standard conditions yielded 
32.6 mg of 4b in 83% yield. 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.29 (m, 2H), 7.29 – 
7.26 (m, 1H), 7.22 – 7.18 (m, 2H), 4.31 (m, 1H), 3.23 (dd, J = 14.0, 7.0 Hz, 1H), 3.07 
(dd, J = 14.0, 7.3 Hz, 1H), 1.70 (d, J = 6.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 138.5, 




Reaction of 29.6 mg 4-allyl anisole with HBr-DMPU under standard conditions after 1 
hour afforded 40.2 mg of 4c in 87% yield. 1H NMR (400 MHz, CDCl3) δ 7.14 – 7.12 (m, 
2H), 6.87-6.85 (m, 2H), 4.27 (m, 1H), 3.80 (s, 3H), 3.17 (dd, J = 14.1, 6.9 Hz, 1H), 3.01 
(dd, J = 14.1, 7.3 Hz, 1H), 1.69 (d, J = 6.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 158.5, 




Reaction of 30.3 mg 3-(4-fluorophenyl) propene with HBr-DMPU under standard 
conditions yielded 39.8 mg of 4d in 92% yield. 1H NMR (400 MHz, CDCl3) δ 7.24 – 7.11 
(m, 2H), 7.09 – 6.90 (m, 2H), 4.35 – 4.15 (m, 1H), 3.17 (dd, J = 14.2, 7.3 Hz, 1H), 3.06 
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(dd, J = 14.2, 6.8 Hz, 1H), 1.70 (d, J = 6.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 161.8, 




Reaction of 20.8 mg styrene with HBr-DMPU under standard conditions yielded 30.7 mg 
of 4d in 83% yield after chromatography purification.  1H NMR (400 MHz, CDCl3) δ 7.47 
– 7.42 (m, 2H), 7.38 – 7.32 (m, 2H), 7.31 – 7.26 (m, 1H), 5.22 (q, J = 6.9 Hz, 1H), 2.06 





Reaction of 36.4 mg of tridecene with HBr-DMPU under standard conditions yielded 43.1 
mg of 4f in 82% yield. 1H NMR (400 MHz, CDCl3) δ 4.21 – 4.05 (m, 1H), 1.89 – 1.76 (m, 
2H), 1.70 (d, J = 6.6 Hz, 3H), 1.26 (s, 20H), 0.88 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 





Reaction of 45.1 mg N-homoallyl sulfonamide with HBr-DMPU under standard 
conditions yielded 53.2 mg of 4g in 87% yield. 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 
8.3 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 4.84 (t, J = 6.5 Hz, 1H), 4.13 (ddt, J = 9.7, 6.7, 3.8 
Hz, 1H), 3.28 – 2.98 (m, 2H), 2.43 (s, 3H), 2.05 – 1.95 (m, 1H), 2.13 – 1.80 (m, 1H), 1.67 
(d, J = 6.7 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 143.5, 136.7, 129.8, 127.1, 127.0, 




Reaction of 40.2 mg homoallyl phthalimide and HBr-DMPU under standard conditions 
yielded 48.8 mg of 2-4h in 86% yielded. 1H NMR (400 MHz, CDCl3) δ 7.89 – 7.77 (m, 
2H), 7.74 – 7.66 (m, 2H), 4.20 – 4.00 (m, 1H), 3.88 (ddd, J = 14.0, 7.5, 6.6 Hz, 1H), 3.80 
(ddd, J = 13.9, 7.6, 6.8 Hz, 1H), 2.30 – 2.07 (m, 2H), 1.75 (d, J = 6.6 Hz, 3H). 13C NMR 




Reaction of 35.2 mg of homoallyl benzoate with HBr-DMPU under standard conditions 
yielded 47.2 mg of 2-4i in 92% yield. 1H NMR (400 MHz, CDCl3) δ 8.15 – 7.91 (m, 2H), 
7.64 – 7.51 (m, 1H), 7.50 – 7.36 (m, 2H), 4.54 (dt, J = 11.2, 5.6 Hz, 1H), 4.44 (ddd, J = 
11.3, 7.8, 5.7 Hz, 1H), 4.30 (td, J = 8.7, 6.8, 4.9 Hz, 1H), 2.38 – 2.11 (m, 2H), 1.79 (d, J 
= 6.7 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 166.3, 133.0, 130.0, 129.6, 128.4, 63.0, 
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46.9, 39.8, 26.6. HR-MS (ESI): Exact Mass Calcd for C11H13BrNaO2 ([M+Na]+): 
278.99966 Found 278.99940. 
 
Cyclization of 2-4f 
30 mg of 2-4f was dissolved in 1 mL of DMF and the solution was stirred in an ice bath 
for 10 minutes. 12 mg of sodium hydride was added in one portion. Reaction was 
continued for 1 hour and quenched by addition of 1 mL of brine. To reaction mixture, 
silica was added and dried over a rotary evaporator. Final product was obtained after a 




1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.0 Hz, 2H), 7.42 – 7.29 (m, 2H), 4.03 – 3.83 
(m, 1H), 3.67 (dd, J = 8.0, 3.6 Hz, 1H), 3.48 (q, J = 8.7 Hz, 1H), 2.44 (s, 3H), 2.05 – 1.91 
(m, 1H), 1.92 – 1.83 (m, 1H), 1.39 (d, J = 6.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 
132.1, 129.7, 128.4, 125.4, 60.3, 60.2, 47.4, 24.06, 22.3. HR-MS (ESI): Exact Mass 





1H NMR (400 MHz, CDCl3)  δ 7.38 – 7.32 (m, 5H), 4.33 (dd, J = 11.2, 2.1 Hz, 1H), 4.31 – 
4.25 (m, 1H), 4.16 (ddd, J = 12.0, 4.8, 1.7 Hz, 1H), 3.60 (td, J = 12.0, 2.4 Hz, 1H), 2.55 – 
2.42 (m, 1H), 2.30 – 2.18 (m, 2H), 2.11 – 2.05 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 




1H NMR (400 MHz, CDCl3) δ = 7.60 (d, J=8.0, 2H), 7.44 (d, J=8.0, 2H), 4.39 (d, J=11.0, 
1H), 4.28 (dd, J=14.1, 9.8, 1H), 4.17 (dd, J=12.0, 3.0, 1H), 3.60 (t, J=12.1, 1H), 2.48 (d, 
J=12.9, 1H), 2.27 (d, J=13.2, 1H), 2.21 – 2.08 (m, 1H), 2.00 (dd, J=24.2, 12.0, 1H). 13C 
NMR (100 MHz, CDCl3) δ = 145.1, 129.8, 125.9, 125.4, 122.7, 79.5, 68.2, 45.6, 37.5. 19F 




1H NMR (400 MHz, CDCl3) δ = 7.89 – 7.72 (m, 4H), 7.45 (t, J=7.2, 3H), 4.50 (d, J=11.4, 
1H), 4.34 (t, J=12.1, 1H), 4.20 (d, J=11.9, 1H), 3.66 (t, J=12.0, 1H), 2.57 (d, J=12.3, 1H), 
2.35 – 2.06 (m, 3H). 13C NMR (100 MHz, CDCl3) δ 138.5, 133.3, 133.0, 128.3, 128.2, 





Reaction of 40.5 mg allene 3a with HBr-DMPU under standard conditions afforded 30.5 
mg of 4a in 54% yield. 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.29 (m, 5H), 5.17 (s, 2H), 
3.63 (s, 2H), 1.92 (s, 3H), 1.80 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 135.7, 135.3, 
128.5, 128.2, 128.1, 110.6, 66.7, 43.4, 20.7. 
 



























































































































































































3. CHLORIDE-TOLERANT GOLD(I) CATALYZED 




Chlorination is one of the most important transformations in organic synthesis because 
of the biological activities and synthetic value of the chlorinated products.1 More 
specifically, vinylchloride is one of the most important group of chlorine-containing 
compounds. Vinylchlorides are widely found in natural products, pharmaceuticals and 
agrochemicals,1, 73 and also are valuable coupling partners in coupling reactions such as 
Buchwald-Hartwig amination74 and Suzuki-Miyaura coupling.75 Compared to the 
traditional syntheses of vinylchlorides, such as halogenations of carbonyl compounds67b, 
76 and electrophilic chlorination of alkynes,77 the direct hydrochlorination of alkynes from 
HCl is a straightforward and atom-economic method. However, given that HCl itself is a 
dangerous gas and handling is problematic, synthetic chemists have focused on indirect 
hydrochlorination strategies for activated alkynes,4a, b, 78 using RCOCl, TMSCl or metal 
chlorides as chlorine sources (Scheme 3a).4d, 79 One notable example is the recent work 
by Engle and coworkers on the palladium-catalyzed anti-hydrochlorination of alkynes 
using a directing group (Scheme 3b).80 The direct hydrochlorination of unactivated 
alkynes using HCl has been rarely reported. Dai and coworkers found that gaseous HCl 
could hydrochlorinate electron-rich phenylacetylenes but the use of gaseous HCl, and 
hydration side products present major drawbacks.81 Derien and coworkers developed a 
ruthenium-catalyzed hydrochlorination of alkynes that gave good yields (Scheme 3c).43a 
Although this method works well for terminal alkynes, higher temperature was needed 
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and low stereoselectivity was observed for internal alkynes. Moreover, a restrictive 
Schlenk environment was essential.  
Scheme 3. Major synthetic methods for chlorination of alkynes to synthesize 
vinylchlorides 
 
The heterogeneous gold catalyzed hydrochlorination of acetylene for manufacture of 
vinyl chloride monomer (VCM) is a well-studied process,82 and has been industrialized 
recently (Scheme 3d).83 Recently, and independently, Corma group84 and our group85 
reported a heterogeneous gold (TiO2/Au) catalyzed hydrochlorination reaction of 
alkynes. Although good syn-addition selectivity was observed, high temperatures were 
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needed (Scheme 3d). Though homogeneous cationic gold catalysts are considered as 
the most powerful catalysts for the electrophilic activation of alkynes,86 the cationic gold-
catalyzed hydrochlorination of alkynes has not been reported because of the high affinity 
between cationic gold and chloride.87 Indeed, commonly used gold pre-catalysts, such 
as PPh3AuCl, usually need silver salts to break the strong Au-Cl bond and release an 
active cationic gold species and chloride is known to easily poison cationic gold species 
(Scheme 4a).88 We are now pleased to report a homogenous gold-catalyzed alkyne 
hydrochlorination with exclusive anti-selectivity that overcomes the incompatibility 
between cationic gold catalysts and chloride (Scheme 3e). 
We proposed that a combination of strong hydrogen bond donor solvents such as 
hexafluoroisopropanol (HFIP), and HCl would generate a strong hydrogen bonding 
donor network A, and that the hydrogen bonding between chlorine in L-Au-Cl and A 
might weaken the Au-Cl bond (Scheme 4b). This would generate a partially cationic gold 
species B via hydrogen bonding interaction. This strategy would avoid the use of a silver 
salt to activate the gold pre-catalyst, a step that is known to exert negative effects in gold 
catalysis.89  
Scheme 4. Conventional cationic gold catalysis and chloride-tolerant 
homogenous gold catalysis  
66 
 
3.2. Results and discussion 
We used 4-phenylbutyne 3-1a as the model substrate for reaction optimization. We 
screened various ligands, HCl sources and solvents (Table 5). Due to its high hydrogen 
bond basicity but low Brønsted basicity,90,6 DMPU is able to form a stable and highly 
concentrated complex with hydrogen chloride (HCl).15 Using 1.5 equiv of HCl/DMPU and 
2 mol % of gold catalyst and various ligands (3-L1 to 3-L6) led to high yields of product 
(Table 5, entries 1-6). However, the anti-Markovnikov and dichlorinated products were 
also obtained in varying amounts. The use of 3-L5 improved the selectivity of the 
produced vinylchloride to 95 % yield, needing only 1.2 equiv of HCl/DMPU (Table 5, 
entry 7). Formation of the dichlorinated byproduct was avoided by running the reaction at 
ambient temperature (Table 5, entry 8-9), with both 3-L5 and 3-L6 working equally well. 
A poor yield was obtained in the absence of gold (Table 5, entry 10). Notably, lower 
selectivity and poor yields were observed when commercially available HCl sources 
(HCl/iPrOH and HCl/ether) were used (Table 5, entries 11 and 12). We screened other 
solvents to further optimize the regioselectivity. We found that a 1:1 HFIP: CH3NO2 
mixture provided optimal conditions. It is worth noting that tert-butanol and THF gave 
substantial amounts to the corresponding ketone.  
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Table 5. Screening of homogeneous gold catalyzed hydrochlorination of alkynes 
 




1 L1 1.5 HCl/DMPU HFIP 80 75:8:17 
2 L2 1.5 HCl/DMPU HFIP 55 76:9:15 
3 L3 1.5 HCl/DMPU HFIP 65 90:8:2 
4 L4 1.5 HCl/DMPU HFIP 38 82:9:9 
5 L5 1.5 HCl/DMPU HFIP 95 93:4:3 
6 L6 1.5 HCl/DMPU HFIP 96 90:7:3 
7 L5 1.2 HCl/DMPU HFIP 95 95:4:1 
8b L5 1.2 HCl/DMPU HFIP 98 97:3: - 
9b L6 1.2 HCl/DMPU HFIP 95 97:3: - 
10 - 2.4 HCl/DMPU HFIP 34 59:16:25 
11b L5 1.2 HCl/iPrOH HFIP 72 88:12: - 
12b L5 1.2 HCl/Et2O HFIP <5 n. a. 
13b, c L6 1.2 HCl/DMPU tBuOH 85 51: -: - 
14b, c L6 1.2 HCl/DMPU THF 78 82:8: - 
15b, d L6 1.2 HCl/DMPU HFIP/MeNO2 97 99:1: - 
16b, d L6 1.2 HCl/DMPU      HFIP/ DMF 93 98:2: - 
aYields were determined by GC-MS using dodecane as internal standard. bReaction run at rt for    24 h. 
cKetone product formed (accounts for the remaining ratio of product). dSolvent mixture is 1:1 by volume. 
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A 1:1 HFIP: DMF combination worked well also (Table 5, entry 16). With optimized 
conditions in hand, we investigated the substrate scope (Table 6). We first examined the 
scope of aliphatic alkynes. A wide variety of terminal alkynes reacted smoothly to give 
the corresponding vinylchlorides in good to excellent yields. Nitrile (3-2b), ester (3-2d), 
imide (3-2e), sulfide (3-2f), amide (3-2u), and ketone ether (3-2v) functional groups were 
well tolerated under the standard conditions. The reaction with derivatized amino acid (3-
2u) and the natural product estrone (3-2v) led to the corresponding products in 69 % 
and 95 % yield, respectively. The internal alkyne 4-octyne (3-2c) also worked well, 
although higher temperature and longer reaction time were needed. When we explored 
the scope of arylacetylenes we found good to excellent yields using electron-rich and 
electron-deficient arylacetylenes. Para (3-1h), meta (3-1i) and ortho (3-1j) 
tolylacetylenes furnished the corresponding vinylchlorides in excellent yields. It is worth 
noting that electron deficient arylacetylenes gave increasing amounts of the anti-
Markovnikov products (3-2n, 3-2o, 3-2p, and 3-2q). A remarkable example was the 
heteroaromatic alkyne 2-ethynylpyridine (3-1r), which was expected to quench the 
reactivity of homogenous cationic gold due to its basic nature, but under our conditions, 
3-1r furnished the anti-Markovnikov vinylchloride (3-2r) in 70 % yield. The pyridinyl 
nitrogen acting as a directing group and coordinating with HCl or gold could have caused 
the change of regioselectivity in 3-2r. 3-Ethynylthiophene (3-1s) gave an excellent yield 
of the corresponding chloro product. The electron deficient internal alkyne 
ethylphenylpropiolate (3-1t) also worked well, albeit a higher temperature (75oC) was 
needed, and the yield was modest (66%). In this case, a mixture of E/Z isomers was 
obtained, possibly due to the isomerization caused by the elevated temperature. It 
should be noted that our homogenous gold catalyzed reaction required milder conditions 
(room temperature) than the recently reported heterogeneous gold catalyzed process, 
and that the stereochemistry of the addition was different.84 
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Table 6. Substrate scope of homogeneous gold catalyzed hydrochlorination of 
alkynes 
 
Due to the milder conditions of our reaction, we expected better functional group 
tolerance. Indeed, the peptide (3-2u) and derivatized estrone (3-2v) were tolerated 
under our conditions. The homogenous gold process gave the anti-addition pattern 
(Table 6, 3-2c and 3-2r), which is consistent with typical homogeneous gold catalysis 
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where cationic gold activates alkyne substrates. On the other hand, the nanogold 
catalyzed process gave syn-addition products, which suggests that nano-gold initially 
activates HCl rather than the alkyne.84 
Scheme 5. Gram-scale synthesis and the synthetic utility of vinylchlorides 
 
 
Our strategy for the hydrochlorination of unactivated alkynes was easily expanded to 
large-scale synthesis, without affecting yield and regioselectivity (Scheme 5a). To 
examine the synthetic value of the synthesized vinylchlorides, we conducted two classic 
reactions that use vinyl chlorides as building blocks, namely the Suzuki coupling and the 
Buchwald–Hartwig amination. In both cases, the desired products were isolated in good 
yields (Scheme 5b and Scheme 5c).   
 
3.3. Conclusion 
In conclusion, we have accomplished the first efficient regioselective homogeneous 
gold-catalyzed hydrochlorination of unactivated alkynes. We have overcome the 
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traditional incompatibility between conventional cationic gold catalysts and chloride. This 
method can be easily scaled up, and the reactions can be conducted in the open air.  
3.4. Experimental 
3.4.1. General  
1H and 13C NMR spectra were recorded at 400 MHz and 101 MHz using CDCl3 as a 
solvent. The chemical shifts are reported in δ (ppm) values (1H and 13C NMR relative to 
CHCl3, δ 7.26 ppm for 1H NMR and δ 77.0 ppm for 13C NMR and CFCl3 (δ 0 ppm for 19F 
NMR), multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), p 
(pentet), h (hextet), m (multiplet) and br (broad). Coupling constants (J), are reported in 
Hertz (Hz). All reagents and solvents were employed without further purification. The 
products were purified using a commercial flash chromatography system. TLC was 
developed on silica gel 60 F254 aluminum sheets. All reagents were purchased from 
Sigma-Aldrich or Alfa Aesar and used as received without any further purification.  
3.4.2. Reagent preparation  
A general assembly is indicated below. All operations were conducted in well ventilated 
fume hoods. 
Figure 8. Set-up for the preparation of HCl/DMPU 
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A pressure-equalizing dropping funnel and inlet of a drying tube packed with CaCl2 were 
attached onto a 500 mL of two-neck round-bottom flask. The outlet of the drying tube 
was attached to one joint of 100 mL two-neck round-bottom flask through tubing; a 5’’ 
pipette was attached to the end of the tubing. The other joint of the same flask was 
attached to the second drying tube connected to a base bath (Figure 8). After flushing 
the whole system by argon for 10 minutes, sodium chloride and a stirring bar were 
placed in the 500 mL two-neck flask, the dropping funnel was charged with concentrated 
sulfuric acid, and DMPU and a small stirring bar were placed in a 100 mL receiving flask. 
Both flasks were cooled in ice-water baths.  Concentrated sulfuric acid was then 
gradually dropped onto sodium chloride at a rate of one drop per second, and an 
extremely exothermic reaction took place. During the absorption of HCl, the colorless 
DMPU turned into a viscous yellowish liquid.  The obtained HCl/DMPU solution was 
pipetted into an argon-flushed glass vessel with PTFE-lined cap. The concentration of 
the generated HCl/DMPU was approximately 43% by weight. This solution is slightly 
fuming but stable over months on a lab bench. 
3.4.3. Synthesis of gold complexes (L-AuCl) 
All gold complexes (L-AuCl) were synthesized using a slightly modified version of a 
literature method.91 These complexes were prepared via either one of the following 
general procedures, and the characterization of these gold complexes were previously 
reported by us.92  
Method 1: Sodium tetrachloroaurate(III) dihydrate (1 mmol) was dissolved in water, and 
the orange solution was cooled in ice. To this solution, 2,2’-thiodiethanol (3 mmol) was 
slowly added (ca. 10 min) with stirring. After stirring at 0oC for another 30 min, a solution 
of the phosphine ligand (1 mmol) in EtOH (if the ligand could not be dissolved, more 
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EtOH was used) was added dropwise to yield a white solid. The solid was filtered off, 
washed with water followed by EtOH, and ultimately dried in vacuum. 
Method 2: Chloro(dimethylsulfide)gold(I) (1 mmol) was dissolved in dichloromethane in 
a vial and cooled in an ice bath. A solution of phosphine ligand (1 mmol) in 
dichloromethane was added dropwise, and the resulting solution was allowed to warm to 
room temperature and stirred at room temperature for 3 h. After TLC indicated complete 
consumption of the starting material, the reaction solution was concentrated to dryness 
in the rotovap, and the gold complex product was further dried under high vacuum. 
3.4.4. General procedure for homogeneous gold catalyzed 
hydrochlorination of alkynes 
A glass screw cap vial equipped with a stir bar was charged with alkyne 3-1 (0.5 mmol). 
A 1:1 mixture of hexafluoroisopropanol (HFIP) and nitromethane (125 µL) was added to 
dissolve it. 3-L6-Au-Cl (7.3 mg, 2 mol %) was then added followed by HCl/DMPU (48 µL, 
0.6 mmol). The reaction mixture was stirred at rt (or 75 oC as the case may demand) and 
the progress of the reaction was monitored by GCMS or 1H-NMR. Upon completion, 
reaction mixture was quenched with water and extracted with DCM. It was then dried 
over anhydrous Na2SO4, filtered and solvent evaporated. The crude product was purified 
by silica gel column chromatography (hexanes/ethyl acetate). 
3.4.5. Procedure for synthesis of 3-4 
 
Boronic acid (0.3 mmol, 49.8 mg), Pd(dppf)Cl2 (5 mol %) and Na2CO3 (0.6 mmol, 63.6 
mg) were place into an oven-dried vial, then the vial was vacuumed and purged with 
argon for three times. Vinylchloride (0.2 mmol, 29.3 mg), EtOH (0.3 ml), toluene (0.3ml) 
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and H2O (0.3 mL) were injected into the vial through syringe. The vial was placed into a 
preheated oil bath at 100 oC. The mixture was left to stir overnight. The reaction mixture 
was cooled down to room temperature and diluted with ethyl acetate (EA) (2 mL). Then 
the solution was washed with NaHCO3 (aq.). The organic phase was dried over Na2SO4. 
Then Na2SO4 was filtered off. After evaporation of solvent, the residue was purified by 
flash chromatography on silica gel to obtain 3-4 (EA:Hex=1:15). 
3.4.6. Procedure for synthesis of 3-5 
 
 
Aniline (0.22 mmol, 27.1 mg), Pd2(dba)3 (3 mol %, 5.49 mg), BINAP (5 mol %, 6.23 mg) 
and t-BuONa (0.28 mmol, 26.9 mg) were place into an oven-dried vial, then the vial was 
vacuumed and purged with argon for three times. Vinylchloride (0.2 mmol, 29.3 mg) and 
toluene (1 mL) were injected into the vial through syringe. The vial was placed into a 
preheated oil bath at 100 oC. The mixture was allowed to stir for overnight. The reaction 
mixture was cooled down to room temperature and toluene was evaporated, followed by 
adding DCM (1 mL) into the mixture. Then NaBH(OAc)3 (0.4 mmol, 42.4 mg) and AcOH 
(0.4 mmol, 11.4 µL) were added. The reaction mixture was stirred for 24 h at room 
temperature, then quenched with 1 M NaOH solution, extracted by DCM (2 mL). The 
organic phase was washed with H2O and brine, dried over Na2SO4. Na2SO4 was then 
filtered off, the solvent was evaporated and the residue was purified by flash 
chromatography on silica gel to obtain 5 (EA:Hex=1:8).    
3.4.7. Characterization of products 




1H NMR (400 MHz, CDCl3) δ 7.34 – 7.26 (m, 2H), 7.24 – 7.16 (m, 3H), 5.14 (s, 1H), 5.08 
(s, 1H), 2.96– 2.80 (t, J = 8.0 Hz, 2H), 2.69 – 2.57 (t, J = 8.0 Hz, 2H). 13C NMR (100 
MHz, CDCl3) δ 141.9, 140.5, 128.4, 126.1, 112.5, 112.7, 41.0, 33.6. Colorless oil, 159.4 
mg, 96 % yield. 
5-chlorohex-5-enenitrile (3-2b)   
 
1H NMR (400 MHz, CDCl3) δ 5.23 (s, 2H), 2.50 (t, J = 7.0 Hz, 2H), 2.36 (t, J = 7.0 Hz, 
2H), 2.02-1.89 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 139.9, 119.0, 114.3, 37.5, 22.6, 
15.7. Colorless oil, 126.4 mg, 98 % yield. 
(Z)-4-chlorooct-4-ene (3-2c)  
 
1H NMR (400 MHz, CDCl3) δ 5.42 (t, J = 6.9 Hz, 1H), 2.26 (t, J = 7.2 Hz, 2H), 2.13 (q, J 
= 7.2 Hz, 2H), 1.55 (dd, J = 14.7, 7.4 Hz, 2H), 1.39 (dd, J = 14.7, 7.4 Hz, 2H), 0.89 (dt, J 
= 9.7, 7.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 134.5, 125.1, 41.4, 30.5, 21.9, 20.5, 
13.7, 12.9. Colorless oil, 132.9 mg, 91 % yield. 
5-chlorohex-5-en-1-yl benzoate (3-2d)  
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1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 8.1 Hz, 2H), 7.55 (dd, J = 10.8, 4.0 Hz, 1H), 
7.44 (t, J = 7.6 Hz, 2H), 5.16 (d, J = 7.4 Hz, 2H), 4.33 (t, J = 6.1 Hz, 2H), 2.41 (t, J = 6.9 
Hz, 2H), 1.87 – 1.67 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 166.6, 142.3, 132.9, 130.3, 
129.5, 128.3, 112.5, 64.5, 38.6, 27.6, 23.6. Colorless oil, 226.2 mg, 95 % yield. 
2-(10-chloroundec-10-en-1-yl)isoindoline-1,3-dione (3-2e) 
 
1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 5.0, 3.0 Hz, 2H), 7.69 (dd, J = 5.1, 2.9 Hz, 
2H), 5.09 (d, J = 8.4 Hz, 2H), 3.65 (t, J = 7.2 Hz, 2H), 2.29 (t, J = 7.4 Hz, 2H), 1.68 – 
1.61 (m, 2H), 1.57 – 1.48 (m, 2H), 1.35 – 1.26 (m, 2H). 13C NMR (100 MHz, CDCl3) 
δ168.4, 143.1, 133.8, 132.2, 123.1, 111.7, 39.1, 38.0, 29.3, 29.2, 29.1, 28.5, 28.4, 27.1, 
26.8. HRMS (ESI) calcd. for [C19H24NClONa+] ([M+Na+]) 356.1393; found 356.1385. 
White solid, 303.1 mg, 91 % yield. 
(7-chlorooct-7-en-1-yl)(phenyl)sulfane (3-2f)  
 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.13 (m, 5H), 5.11 (d, J = 11.9 Hz, 2H), 2.90 (t, J = 
7.3 Hz, 2H), 2.31 (t, J = 7.4 Hz, 2H), 1.70 – 1.59 (m, 2H), 1.60 – 1.50 (m, 2H), 1.49 – 
1.38 (m, 2H), 1.37 – 1.26 (m, 2H). 13C NMR (100 MHz, CDCl3) δ = 142.9, 136.9, 128.9, 
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128.8, 125.7, 111.9, 39.0, 33.51, 28.9, 28.4, 28.0, 26.9. Colorless oil, 215.9 mg, 85 % 
yield. 
(1-chlorovinyl) benzene (3-2g)  
 
1H NMR (400 MHz, CDCl3) δ 7.72 – 7.55 (m, 2H), 7.39 – 7.34 (m, 3H), 5.77 (d, J = 1.7 
Hz, 1H), 5.53 (d, J = 1.7 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 139.9, 136.9, 129.1, 
128.3, 126.4, 112.4. Colorless oil, 126.9 mg, 92 % yield.  
1-(1-chlorovinyl)-4-methylbenzene (3-2h)  
 
1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.1 Hz, 2H), 7.17 (d, J = 7.9 Hz, 2H), 5.72 (d, J 
= 1.2 Hz, 1H), 5.47 (d, J = 1.1 Hz, 1H), 2.37 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 




1H NMR (400 MHz, CDCl3) δ 7.45 – 7.43 (m, 2H), 7.27 – 7.16 (m, 2H), 5.75 (s, 1H), 5.51 
(s, 1H), 2.38 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 140.1, 137.9, 136.9, 129.8, 128.2, 
127.1, 123.5, 112.5, 21.4. Colorless oil, 121.6 mg, 80 % yield. 
1-(1-chlorovinyl)-2-methylbenzene (3-2j) 
 
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.11 (m, 4H), 5.64 (d, J = 1.1 Hz, 1H), 5.34 (d, J = 
1.1 Hz, 1H), 2.42 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 139.5, 138.7, 135.8, 130.4, 
128.9, 125.7, 116.5, 116.4, 19.8. Colorless oil, 136.8, 90 % yield. 
1-(tert-butyl)-4-(1-chlorovinyl) benzene (3-2k)  
 
1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 5.73 (s, 
1H), 5.47 (s, 1H), 1.32 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 152.3, 139.9, 134.1, 126.1, 




1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 8.0 Hz, 2H), 5.65 (d, J 
= 1.7 Hz, 1H), 5.41 (d, J = 1.7 Hz, 1H), 3.82 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
160.3, 139.6, 129.5, 127.7, 113.6, 110.8, 55.3. Colorless oil, 139.4 mg, 83 % yield. 
1-(1-chlorovinyl)-4-fluorobenzene (3-2m)  
 
1H NMR (500 MHz, CDCl3) δ 7.64 – 7.61 (m, 2H), 7.08 – 7.05 (m, 2H), 5.72 (d, J = 1.8 
Hz, 1H), 5.52 (d, J = 1.8 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 163.2 (d, J = 199 Hz), 
138.9, 133.1, 128.3, 115.3, 112.6. Colorless oil. 19F NMR (376 MHz, CDCl3) δ -112.28. 
Pale yellow oil, 135.7 mg, 87 % yield. 
methyl 4-(1-chloroethenyl) benzoate (3-2n) 
 
1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 8.3 Hz, 2H), 5.85 (d, J 
= 1.5 Hz, 1H), 5.60 (d, J = 1.5 Hz, 1H), 3.90 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
166.4, 140.9, 138.9, 130.5, 129.5, 126.3, 114.6, 52.1. Yellow solid, 158.7 mg, 81 % 
yield. 
1,4-di(1-chloroethenyl) benzene (3-2o) 
80 
 
1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 1.0 Hz, 4H), 5.81 (d, J = 1.3 Hz, 2H), 5.56 (d, J 
= 1.3 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 139.1, 137.4, 126.3, 113.4. White solid, 
148.5 mg, 75 % yield. 
4-(1-chlorovinyl) benzonitrile (3-2p) 
 
1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H), 5.88 (d, J 
= 2.0 Hz, 1H), 5.67 (d, J = 2.0 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 138.1, 132.7, 
132.2, 126.9, 118.3, 115.8, 112.6. White solid, 130.4 mg, 80 % yield. 
1-(1-chlorovinyl)-4-nitrobenzene (3-2q)  
 
1H NMR (400 MHz, CDCl3) 2r: δ 8.21 (d, J = 8.6 Hz, 2H), 7.79 (t, J = 9.4 Hz, 2H), 5.99 – 
5.86 (m, 1H), 5.72 (d, J = 1.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) 2r/2r’: δ 142.7, 140.4, 
129.9, 127.5, 127.3, 123.6, 123.5, 121.8, 116.41. Yellow solid, 135.4 mg, 74 % yield. 
(Z)-2-(2-chlorovinyl) pyridine (3-2r) 
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1H NMR (700 MHz, CDCl3) δ 8.62 (d, J = 3.5 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.71 (td, 
J = 7.8, 1.6 Hz, 1H), 7.19 (dd, J = 6.5, 4.9 Hz, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.48 (d, J = 
8.4 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 153.2, 149.5, 136.1, 130.4, 124.1, 122.6, 
120.51. Yellow oil, 97.3 mg, 70 % yield. 
3-(1-chlorovinyl) thiophene (3-2s) 
 
1H NMR (400 MHz, CDCl3) δ 7.52 (s, 1H), 7.33 – 7.20 (m, 2H), 5.69 (s, 1H), 5.43 (s, 
1H). 13C NMR (100 MHz, CDCl3) δ 138.9, 134.6, 126.4, 125.0, 124.3, 111.4. Yellow oil, 
138.2 mg, 96 % yield. 
(Z)-ethyl 3-chloro-3-phenylacrylate and (E)-ethyl 3-chloro-3-phenylacrylate (3-2t)  
 
1H NMR (500 MHz, CDCl3) (Z) δ 7.71- 7.69 (m, 2H), 7.57 – 7.34 (m, 3H), 6.56 (s, 1H, Z), 
6.37 (s, 1H, E), 4.29 (q, J = 7.1 Hz, 2H, Z), 4.07 (q, J = 7.1 Hz, 2H, E), 1.35 (t, J = 7.1 
Hz, 3H, Z), 1.13 (t, J = 7.1 Hz, 3H, E).  13C NMR (126 MHz, CDCl3) Z/E: δ 164.2, 163.8, 
149.7, 146.1, 137.3, 130.6, 129.9, 128.6, 128.4, 127.8, 127.2, 119.9, 116.4, 60.6, 14.2, 
13.9. Colorless liquid, 138.6 mg, 66 % yield 
(S)-methyl 2-(5-chlorohex-5-enamido)-3-phenylpropanoate (3-2u)  
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1H NMR (400 MHz, CDCl3) δ 7.28-7.25 (m, 3H), 7.09-7.07 (m, 2H), 7.57-7.54 (m, 1H), 
5.86 (s, 1H), 5.11 (d, J = 24.0 Hz, 2H), 4.92-4.87 (m, 1H), 3.73 (s, 1H), 3.16-3.05 (m, 
2H), 2.33 (t, J = 8.0 Hz, 2H), 2.18 (t, J = 8.0 Hz, 2H), 1.90-1.85 (m, 2H). 13C NMR (100 
MHz, CDCl3) δ 172.1, 171.8, 141.8, 135.7, 129.2, 128.6, 127.2, 112.9, 52.9, 52.3, 38.1, 
37.8, 34.6, 22.7. HRMS (ESI) calcd. for [C16H20NClO3Na+] ([M+Na+]) 332.1029; found 
332.1031. Colorless oil, 213.3 mg, 69 % yield. 
(8R,9S,13S,14S)-3-((7-chlorooct-7-en-1-yl)oxy)-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one (3-2v)  
 
1H NMR (400 MHz, CDCl3) δ 7.18 (d, J=8.0 Hz, 1H), 6.71-6.69 (m, 1H), 6.63 (s, 1H), 
5.11 (d, J = 8.0 Hz, 2H), 3.91 (t, J = 8.0 Hz, 2H), 2.90-2.87 (m, 2H), 2.52-2.45 (m, 2H), 
2.39-2.31 (m, 3H), 2.26-2.22 (m, 1H), 2.18-1.93 (m, 4H), 1.80-1.73 (m, 2H), 1.64-1.37 
(m, 11H), 0.90 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 220.9, 157.1, 142.9, 137.7, 131.9, 
126.3, 114.5, 114.5, 112.1, 111.9, 67.7, 50.4, 47.9, 43.9, 39.0, 38.4, 25.9, 31.6, 29.6, 
29.2, 28.2, 27.1, 26.6, 25.9, 25.8, 21.6, 13.8. HRMS (ESI) calcd. for [C26H35ClO2Na+] 




1H NMR (400 MHz, CDCl3) δ 6.90-6.87 (m, 2H), 6.76 (d, J = 8.0 Hz, 1H), 5.94 (s, 2H), 
5.15 (s, 1H), 4.96 (s, 1H), 2.42 (t, J = 8.0 Hz, 2H), 1.42 – 1.19 (m, 8H), 0.87 (t, J = 8.0 
Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 148.2, 147.6, 146.7, 135.8, 119.5, 111.1, 
107.9, 106.7, 100.9, 35.6, 31.7, 28.9, 28.3, 22.6, 14.1. Colorless oil, 174.1 mg, 75 % 
yield. 
 4-methoxy-N-(octan-2-yl) aniline (3-5)  
 
1H NMR (400 MHz, CDCl3) δ 6.76 (d, J = 8.0 Hz, 2H), 6.55 (d, J = 8.0 Hz, 2H), 3.74 (s, 
1H), 3.37-3.33 (m, 1H), 3.05 (s, 1H), 1.36-1.27 (m, 10H), 1.14 (d, J = 8.0 Hz, 3H), 0.88 
(t, J = 8.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 151.8, 141.9, 114.9, 114.6, 55.9, 49.6, 
37.2, 31.8, 29.4, 26.1, 22.6, 20.81, 14.0. Colorless oil, 157.6 mg, 67 % yield. 
84 























































































4. METEL-FREE CHLOROTHIOLATION OF 
ALKENES USING HCl AND SULFOXIDES
 
4.1 Introduction 
Carbon-sulfur bond forming reactions are highly desirable because sulfur-containing 
compounds are commonly found in biologically important natural and synthetic 
products,93 and functionalized materials.94 These applications drive the investigation of 
new carbon-sulfur bond forming reactions.95 The difunctionalization of alkenes is a 
fundamentally important transformation in organic synthesis.96 More specifically, 1,2-
chlorothiolation of olefins installs both the chloro- and thio-groups simultaneously. The 
resulting β-chlorothiolated compounds have been shown to possess insecticidal, 
antibacterial and antifungal properties.97 Chlorothiolated compounds are commonly 
synthesized via electrophilic addition of sulfenylchlorides to olefins.97a, 98 Recently, 
chloromethylsulfide was shown to be the species responsible for the chlorothiolation of 
alkynes.99 However, this method presents certain challenges: the instability and volatility 
of lower alkylsulfenyl chlorides require extremely low reaction temperatures.  
Dimethylsulfoxide (DMSO), which is an environmentally benign and easy to handle 
reagent, has been utilized in the past decade as a one-carbon synthon for C-C 
homologation100 and as the source of the thiomethyl moiety101 as well as other 
reactions.102 Several DMSO-Lewis acid combinations have been employed with chloride 
and bromide sources to achieve β-halothiolation.103  Pagnoni and co-workers103c 
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reported the transformation of alkenes to their corresponding β-chloromethylthiolated 
products using dialkylsulfoxide-trimethylchlorosilane [R2SO-(CH3)3SiCl]. They 
subsequently used a dimethylsulfoxide-dimethylsulfide-sulfuryl chloride (DMSO-DMS-
SO2Cl2) combination to achieve the same transformation (Scheme 6a). The importance 
of incorporating the thiomethyl moiety within molecules has engrossed research 
interests lately as demonstrated by the DMSO-mediated thiomethylation of arenes 
(Scheme 6b).95b-d The above methods suffer from poor atom economy or use of strong 
oxidants and expensive transition metal catalysts. We reasoned that the reactive 
chlorosulfonium species can be generated in situ directly from a sulfoxide and a 
Brønsted acid like HCl, which can then react with unactivated alkenes to give β-
chlorothiolated compounds in an atom-economical fashion (Scheme 6c). 
Scheme 6. Chlorothiolation of alkenes and arenes 
 
 
4.2 Results and discussion 
 We began our investigation using allylbenzene (4-1a) as the model substrate (Table 7). 
Using ethyl acetate as choice solvent104, no reaction took place when aqueous 
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concentrated aqueous HCl (37%) was employed (Table 7, entry 1). However, using our 
newly developed DMPU-HCl reagent,8, 105 we succeeded in generating the reactive 
methylsulfinyl chloride, which then reacted with allylbenzene to give the desired product 
(Table 7, entry 2). Increasing the amounts of DMSO (Table 7, entries 3-4) gave 
complete conversion in a shorter reaction time. When the reaction was run in more dilute 
conditions, the conversion was reduced (Table 7, entry 5). Concentrated aqueous HCl 
(37%) also resulted in moderate conversion at higher temperatures (Table 7, entry 6). 
Commercial 5M HCl/isopropanol solution (Table 7, entry 5) also gave good conversion, 
but suffered from the formation of side products due to further reaction with isopropanol. 
Table 7. Optimization of reaction conditions 
 
Entry X  
(equiv) 






1 1.2 36.6-38% HCl (aq) 0.5 24 trace 
2 1.2 HCl/DMPU (38-42 % w/w) 0.5 24 71 
3 2.4 HCl/DMPU (38-42 % w/w) 0.5 5 100 
4 4.8 HCl/DMPU (38-42 % w/w) 0.5 2 100 
5 2.4 HCl/DMPU (38-42 % w/w) 1 5 95 
6 2.4 36.6-38% HCl(aq) 1 24 54c 
7 4.8 HCl/DMPU (38-42 % w/w) 0.5 2 100 
8 2.4 5M HCl/isopropanol 0.5 5 90 
a Reaction conditions: 4-1a (0.5 mmol), HCl/DMPU (1.2 mmol), DMSO (1.2 mmol), 
EtOAc, 60 oC. b Determined by GC-MS with dodecane as the internal standard.  c 
Reaction run at 70 oC. 
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The optimized reaction conditions were then tested on a range of alkenes (Table 8). A 
wide variety of functional groups were well tolerated giving moderate to excellent yields. 
5-Hexene-1-ol (4-1c) gave the desired transformation with a simultaneous chloride 
substitution of the alcohol in 86% yield. Protected alcohols 4-1d, 4-1e, 4-1f, 4-1i and 4-
1k smoothly furnished the corresponding β-chloromethythiolated products in 82%, 71%, 
65%, 62% and 93% respectively. Pthalimides 4-1g and 4-1h gave the desired 
conversions in 87% and 59% respectively. Worthy of note is the significant loss in 
regioselectivity due to the neighboring group participation of carbonyl and ether oxygen 
adjacent to the alkene. As a result, the allylic substrates resulted in a mixture of 
regioisomers (Table 8, 4-2h and 4-2i). 




Other functionalities like carboxylic acids (4-2j), aldehydes (4-2l) and nitriles (4-2n) were 
equally tolerated furnishing products in moderate to excellent yields. Internal alkenes (4-
1q, 4-1r, 4-1s, 4-1t) also proceeded in 89%, 81%, 80% and 69% yields, respectively. 
The reaction is highly stereoselective giving exclusively the trans-addition products and 
single diastereomers. This result is consistent with the trans-addition product expected in 
the reaction of methylsulfenylchlorides to alkenes.103c, 106 Styrene substrates also worked 
well, but the labile benzylic chloride was hydrolyzed during work up to form 4-2s and 4-
2t in 74% and 82 % yields respectively. The reactive 4-vinylanisole gave a complex 
mixture, possibly due to the instability of the product. 
Given the prevalence of the arylsulfides in bioactive compounds, we sought to extend 
this methodology to the synthesis of substituted arylsulfides. Allylbenzene served as the 
model substrate for the reaction with various arylmethylsulfoxides (Table 9). 
Phenylmethylsulfoxide, p-tolylmethylsulfoxide, 4-bromophenylmethyl sulfoxide and 4-
chlorophenylmethylsulfoxide gave the corresponding arylsulfides 4-3a, 4-3b, 4-3c and 4-
3d in moderate yields. 
However, the electron deficient arylmethylsufoxides 4-3e and 4-3f gave poor yields. In 
these cases, the sulfoxides were mostly reduced to the corresponding sulfides. 
Reactions of dialkylsulfoxides such as dibutylsulfoxide was unsuccessful probably due to 
the slower formation of the reactive intermediate. The use of butylmethylsulfoxide gave 
the chloromethylthiolated product as the major adduct.  
To further explore the scalability and application of this method, we performed a gram-
scale reaction which, upon isolation, was efficiently oxidized to the corresponding 
sulfone, 4-4 (Scheme 7a), all in good yields. 
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Table 9. Sulfoxide substrate scope in the β-chloroarylthiolation of alkenes 
 
 
The process is also amenable to late stage functionalization, as demonstrated by the 
protected sugar 4-1v, the chlorothiolated derivative of which 4-2v was isolated in 46% 
yield (Scheme 7b). The rather unexpected result of 4-2w, gave us another platform for 
further elaboration of our method: using m-vinylbenzoic acid (4-1w), we were pleased to 
observe an intramolecular cyclization to form the methylsufide substituted 
isobenzofuranone. Using 4-fluorostyrene 4-1x, we were able to produce an 
intermolecular β-carbomethylthiolation to produce 4-5 in good yields (Scheme 7c). The 
newly formed β-chloromethylsulfides should also be amenable to other synthetic 
processes such as the base-promoted elimination of HCl to give the corresponding vinyl 
thioether,107  or transition metal catalyzed cross-coupling reactions with boronic acids.108  
The proposed mechanism (Scheme 8) involves the protonation of DMSO, generating 
sulfonium salt I, and subsequent elimination of water to form dimethylsulfonium chloride 
II. The reaction of this highly electrophilic species with another equivalent of HCl leads to 
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another electrophilic sulfur species III. III is then attacked by the alkene to generate the 
thiiranium intermediate IV, which is then trapped by the nucleophilic chloride to obtain 
the chlorothiolated product. 
Scheme 7. Generality and applications of method 
 
 
Both Kharasch109 and Mueller106, 110 reported the formation of a thiiaranium ion in the 
addition of sulfenylhalides to olefins.106, 111 The opening of the cyclic thiiaranium ion IV by 
chloride would follow an SN1-like pathway: the nucleophile (Cl-) preferentially attacks at 
the more hindered position resulting in the trans-addition product.106, 112 Notably, our 
HCl-DMSO system does not work for alkynes.113 
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In conclusion, we have achieved the chloromethylthiolation of alkenes, a transformation 
that affords biologically and synthetically relevant β-chlorothiolated compounds, using 
common and easy to handle starting materials: HCl-DMPU, DMSO and alkenes. The 
procedure shows good functional group compatibility-both terminal and internal alkenes 
are suitable substrates-and is suitable for gram scale synthesis.  
4.4 Experimental 
4.4.1.  General 
1H and 13C NMR spectra were recorded either at 400 MHz or 700 MHz, and 101 MHz 
using CDCl3 or CD2Cl2 as a solvent. The chemical shifts are reported in δ (ppm) values 
(1H and 13C NMR relative to CHCl3, δ 7.26 ppm for 1H NMR and δ 77.0 ppm for 13C 
NMR, multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), p 
(pentet), h (hextet), m (multiplet) and br (broad). Coupling constants (J), are reported in 
Hertz (Hz). The HRMS data was obtained from a Waters Micromass GCT Premier 
spectrometer. All reagents and solvents were employed without further purification. The 
products were purified using a commercial flash chromatography system. TLC was 
117 
developed on silica gel 60 F254 aluminum sheets. All reagents were purchased from 
Sigma-Aldrich or Alfa Aesar and used as received without any further purification.  
4.4.2. General procedure for the β-chloromethyl/arylthiolation of alkenes 
A glass vial equipped with a screw cap and a stirring bar was charged with alkene 4-1 
(0.5 mmol). Then ethyl acetate was added (0.5 mL) followed by DMSO (1.2 mmol) and 
HCl/DMPU (102 µL, 1.2 mmol). The reaction mixture was stirred at 65 oC (or 75 oC for 
less reactive substrates) and the progress of the reaction was monitored by GC-MS or 
TLC. Upon completion, the reaction mixture was quenched with water and extracted with 
DCM. The combined organic layers were then dried over anhydrous Na2SO4, filtered and 
solvent evaporated. The crude product was purified by silica gel column chromatography 
(hexanes/ethyl acetate). 
4.4.3. Procedure for synthesis of sulfone, 4-4 
 
 
Product 4-2a, prepared using general procedure (0.5 mmol, 100 mg), was measured into 
a screw cap vial equipped with a stir bar. Acetic acid (90.5 mL) was added and vial 
placed into an ice-bath to chill to 0 oC. H2O2 (170 µL, 1.7 mmol) was added dropwise and 
the reaction mixture let to stir and warm up to rt. The reaction progress was monitored 
by GCMS and TLC. Upon completion, reaction was quenched with saturated aqueous 
Na2S2O3 (2 mL), extracted with DCM (2 mL), washed twice with water (2 X 2 mL). The 
organic phase was dried over Na2SO4, filtered off and solvent evaporated. The residue 
was purified by flash chromatography on silica gel to obtain 4-4 (1:9 EtOAc:Hex) to yield 
the desired product. Colorless oil, 113.6 mg, 98 %.  
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4.4.4. Procedure for the synthesis of 4-5 
 
A glass screw cap vial equipped with a stir bar was charged with alkene 1 (0.5 mmol). 
Ethylacetate was added (0.5 mL). DMSO (1.2 mmol) and HCl/DMPU (102 µL, 1.2 
mmol). The reaction mixture was stirred at 65 oC and the progress of the reaction was 
monitored by GCMS or 1H-NMR. Upon completion, the reaction mixture was cooled to rt 
then excess pyrrole (3.6 mmol, 0.25 mL) added and the reaction stirred for another 1 h. 
Upon full conversion, reaction mixture was quenched with saturated bicarbonate and 
extracted with DCM. It was then dried over anhydrous Na2SO4, filtered and solvent 
evaporated. The crude product was purified by silica gel column chromatography 
(hexanes/ethyl acetate). 
4.4.5. Characterization of products 
(2-chloro-3-phenylpropyl) methyl sulfide (4-2a)  
 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.18 (m, 5H), 4.30 – 4.14 (m, 1H), 3.32 (dd, J=14.2, 
5.0, 1H), 3.00 (dd, J = 14.1, 8.0, 1H), 2.92 – 2.78 (m, 2H), 2.18 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ 137.2, 129.4, 128.4, 126.8, 61.8, 42.8, 41.7, 16.6. HRMS (EI+) calcd. for 
[C10H13SCl+] (M+) 200.0427; found 200.0425. Pale yellow oil, 89.4 mg, 89 % yield. 
(2-chlorooctyl) methyl sulfide (4-2b)   
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1H NMR (400 MHz, CD2Cl2) δ = 4.08 – 4.02 (m, 1H), 2.91 (dd, J = 13.8, 6.1, 1H), 2.83 
(dd, J = 13.9, 7.4, 1H), 2.17 (s, 3H), 2.01 – 1.94 (m, 1H), 1.76 – 1.64 (m, 1H), 1.42 – 
1.28 (m, 8H), 0.90 (t, J = 6.8, 3H). 13C NMR (100 MHz, CD2Cl2) δ = 62.3, 42.4, 36.8, 
31.6, 28.7, 26.2, 22.5, 16.2, 13.8. HRMS (EI+) calcd. for [C9H19SCl+] (M+)194.0896; 
found 194.0894. Colorless oil, 92.2 mg, 95 % yield. 
(2,6-dichlorohexyl) methyl sulfide (4-2c)  
 
1H NMR (400 MHz, CDCl3) δ = 4.05 – 3.93 (m, 1H), 3.54 (t, J = 6.5, 2H), 2.90 (dd, J = 
13.8, 5.7, 1H), 2.79 (dd, J = 13.8, 8.0, 1H), 2.15 (s, 3H), 2.05 – 1.98 (m, 1H), 1.84 – 1.53 
(m, 6H). 13C NMR (126 MHz, CDCl3) δ = 61.4, 44.7, 42.3, 35.9, 31.9, 23.7, 16.6. HRMS 
(EI+) calcd. for [C10H13SCl2+] (M+) 200.0193; found 200.0195. Colorless oil, 86.1 mg, 86 
% yield. 
(2-chloro-5-benzoylpentyl) methyl sulfide (4-2d)  
 
1H NMR (400 MHz, CDCl3) δ = 8.03 (d, J = 7.6, 2H), 7.55 (t, J = 7.4, 1H), 7.43 (t, J = 7.6, 
2H), 4.36 (t, J = 5.6, 2H), 4.14 – 3.99 (m, 1H), 2.93 (dd, J = 13.9, 5.6, 1H), 2.81 (dd, J = 
13.8, 8.1, 1H), 2.22 – 2.04 (m, 5H), 1.95 – 1.77 (m, 2H). 13C NMR (100 MHz, CDCl3) δ = 
166.5, 132.9, 130.2, 129.5, 128.4, 64.2, 61.1, 42.4, 33.2, 25.6, 16.5. HRMS (EI+) calcd. 
for [C10H17O2SCl+] (M+) 272.0638; found 272.0630. Yellow oil, 111.5 mg, 82 % yield. 
(2-chloro-2-methyl-4-phenoxybutyl) methyl sulfide (4-2e) 
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1H NMR (400 MHz, CDCl3)) δ = 7.30 (dd, J = 8.5, 7.5, 2H), 6.99 – 6.90 (m, 3H), 4.23 
(ddd, J=8.3, 5.8, 2.5, 2H), 3.07 (d, J = 13.8, 1H), 2.99 (d, J = 13.8, 1H), 2.47- 2.30 (m, 
2H), 2.25 (s, 3H), 1.73 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 158.5, 129.5, 120.8, 
114.5, 72.7, 64.4, 49.3, 41.3, 29.9, 18.5. HRMS (EI+) calcd. for [C12H17OSCl+] (M+) 
244.0689; found 244.0691. Colorless liquid, 86.7 mg, 71 % yield. 
(2-chloro-4-phenoxybutyl) methyl sulfide (4-2f)  
 
1H NMR (400 MHz, CDCl3) δ = 7.28 (dd, J = 15.0, 7.5, 2H), 7.04 – 6.81 (m, 3H), 4.40 – 
4.29 (m, 1H), 4.23 – 4.12 (m, 2H), 3.00 (dd, J = 13.9, 6.7, 1H), 2.90 (dd, J = 13.9, 7.7, 
1H), 2.60- 2.52 (m, 1H), 2.20 (s, 3H), 2.13- 2.04 (m, 1H). 13C NMR (100 MHz, CDCl3) δ = 
158.6, 129.5, 120.9, 114.5, 64.3, 58.3, 42.5, 36.4, 16.5. HRMS (ESI) HRMS (EI+) calcd. 
for [C11H15OSCl+] 230.0532; found 230.0536. Colorless oil, 74.6 mg, 65 % yield.  
2-(2-chloro-3-(methylthio)hexyl)isoindoline-1,3-dione (4-2g)  
 
1H NMR (400 MHz, CDCl3) δ = 7.81 (dt, J = 8.2, 3.9, 2H), 7.74 – 7.62 (m, 2H), 4.00- 3.94 
(m, 1H), 3.68 (t, J = 7.1, 2H), 2.88 (dd, J = 13.8, 5.7, 1H), 2.77 (dd, J = 13.8, 7.9, 1H), 
2.13 (s, 3H), 2.10 – 1.97 (m, 1H), 1.79 – 1.58 (m, 5H), 1.54 – 1.38 (m, 1H). 13C NMR 
(100 MHz, CDCl3) δ = 168.3, 133.9, 132.1, 123.2, 61.4, 42.4, 37.6, 36.1, 27.9, 23.5, 
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16.5. HRMS (EI+) calcd. for [C15H18O2NSCl+] 311.0427; found 311.0425. Colorless oil, 
135.3 mg, 87 % yield.  
2-(2-chloro-3-(methylthio)propyl)isoindoline-1,3-dione (4-2h/2h’)  
 
1H NMR (400 MHz, CDCl3) 1H NMR (700 MHz, cdcl3) δ = 7.87 – 7.80 (m, 4H), 7.72 (ddd, 
J = 6.2, 4.7, 3.0, 4H), 4.47- 4.44 (m, 1H, Markonvikov’s product), 4.15 (dd, J = 8.6, 4.8, 
1H), 4.09 – 3.99 (m, 2H), 3.86 (dd, J = 14.2, 8.6, 1H), 3.80 (dd, J = 11.4, 4.8, 1H), 3.66 
(dd, J = 11.4, 8.3, 1H), 3.33- 3.29 (m, 1H, anti-Markovnikov product), 2.95 (dd, J = 14.2, 
5.9, 1H), 2.89 (dd, J = 14.2, 7.7, 1H), 2.20 (s, 3H), 2.13 (s, 3H). 13C NMR (100 MHz, 
CDCl3) δ = 168.0, 134.1, 131.8, 123.5, 57.2, 46.6, 45.5, 43.1, 39.9, 39.0, 16.3, 13.4. 
HRMS (EI+) calcd. for [C12H12SO2NCl+] (M+) 269.0277; found 269.0271. Colorless oil, 
79.4 mg, 59 % yield. 
(2-chloro-4-phenoxypropyl) methyl sulfide (4-2i, 4-2i’) 
 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.21 (m, 4H), 7.10 – 6.86 (m, 6H), 4.38 – 4.19 (m, 
5H), 3.95 – 3.87 (m, 2H), 3.22 – 3.13 (m, 1H), 3.12 – 2.95 (m, 2H), 2.25 (s, 3H), 2.20 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ 158.3, 158.1, 129.6, 121.4, 114.7, 69.7, 67.4, 58.0, 
47.9, 44.3, 38.7, 16.8, 14.9. HRMS (EI+) calcd. for [C10H13OSCl+] (M+) 216.0376; found 
216.0371. Colorless oil, 67.1 mg, 62 % yield. 
10-chloro-11-(methylthio)undecenoic acid (4-2j) 
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1H NMR (400 MHz, CDCl3) δ = 4.13 – 4.08 (m, 2H), 4.02- 3.98 (m, 1H), 2.88 (dd, J = 
13.8, 5.8, 1H), 2.79 (dd, J = 13.8, 7.7, 1H), 2.27 (t, J = 7.5, 2H), 2.15 (s, 3H), 1.95 (td, J 
= 8.6, 4.3, 1H), 1.71 – 1.47 (m, 5H), 1.38- 1.22 (m, 7H). 13C NMR (100 MHz, CDCl3) δ = 
173.8, 61.9, 60.1, 42.5, 36.7, 34.3, 29.1, 28.9, 26.2, 24.9, 16.5, 14.2. HRMS (EI+) calcd. 
for [C12H23O2SCl+] (M+)266.0227; found 266.0225. Colorless oil, 121.1, 91 % yield. 
(2-chloro-2-methyl-4-benzoylbutyl) methyl sulfide (4-2k)  
 
1H NMR (400 MHz, CDCl3) δ = 8.02 (d, J = 7.4, 2H), 7.53 (t, J = 7.4, 1H), 7.41 (t, J = 7.6, 
2H), 4.54 (t, J = 6.7, 2H), 3.04 (dd, J = 13.8, 6.1, 1H), 2.94 (dd, J = 13.9, 7.4, 1H), 2.42- 
2.26 (m, 2H), 2.20 (s, 3H), 1.70 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.4, 132.9, 
130.0, 129.6, 128.4, 71.9, 61.7, 49.2, 40.7, 29.7, 18.4. HRMS (EI+) calcd. for 
[C13H17O2SCl+] (M+) 272.0638; found 272.0630. Pale yellow oil, 126.5 mg, 93 % yield.  
2-formylphenyl 4-chloro-5-(methylthio) pentanoate (4-2l) 
 
1H NMR (400 MHz, CDCl3) δ = 10.06 (s, 1H), 7.86 (d, J = 7.7, 1H), 7.62 (t, J = 7.8, 1H), 
7.40 (t, J = 7.5, 1H), 7.17 (d, J = 8.1, 1H), 4.18 (d, J = 8.2, 1H), 3.00- 2.81 (m, 4H), 2.66 
– 2.50 (m, 1H), 2.16 (s, 3H), 2.09- 2.00 (m, 1H). 13C NMR (100 MHz, CDCl3) δ = 188.8, 
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171.1, 151.1, 135.3, 131.8, 127.9, 126.5, 123.4, 60.4, 42.2, 31.4, 30.9, 16.4. HRMS 
(EI+) calcd. for [C13H17O2SCl+] (M+) 286.0430; found 286.0432. Colorless oil, 70.1 mg, 
49 % yield. 
(2-chloro-4-(naphthalen-2-yloxy)hexyl) methyl sulfide (4-2m)  
 
1H NMR (400 MHz, CDCl3) δ = 7.65 (d, J = 9.5, 1H), 7.55 (dd, J = 7.1, 4.6, 2H), 7.33 (d, 
J = 8.9, 1H), 7.20 (t, J = 7.5, 1H), 6.68 (d, J = 9.5, 1H), 4.38 – 4.19 (m, 2H), 4.00 (dd, J = 
10.0, 6.7, 1H), 2.89 (dd, J = 13.9, 5.7, 1H), 2.79 (dd, J = 13.8, 7.9, 1H), 2.14 (s, 3H), 
1.89 – 1.44 (m, 6H). 13C NMR (100 MHz, CDCl3) δ = 162.1, 139.0, 130.6, 129.0, 121.8, 
121.7, 121.4, 120.9, 114.0, 61.5, 42.4, 42.0, 36.3, 26.8, 23.7, 16.5. HRMS (EI+) calcd. 
for [C16H20O2SNCl+] (M+) 309.1187; found 309.1196. Yellow solid, 80.4 mg, 52 % yield. 
(2-chloro-6-cyanohexyl) methyl sulfide (4-2n) 
 
1H NMR (400 MHz, CDCl3) δ = 4.06 – 3.90 (m, 1H), 2.90 (dd, J = 13.8, 6.1, 1H), 2.78 
(dd, J = 13.9, 7.4, 1H), 2.36 (t, J = 6.5, 2H), 2.15 (s, 3H), 2.07 – 1.98 (m, 1H), 1.76- 1.55 
(m, 5H). 13C NMR (100 MHz, CDCl3) δ = 119.5, 60.9, 42.3, 35.7, 25.5, 24.9, 17.1, 16.6. 
HRMS (EI+) calcd. for [C8H14SNCl+] (M+) 191.0535; found 191.0530. Colorless liquid, 
77.4 mg, 81 % yield. 
(5-chlorooctan-4-yl)(methyl)sulfide (4-2o)  
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1H NMR (400 MHz, CDCl3) δ = 4.11 (d, J=10.0, 1H), 2.73 (s, 1H), 2.13 (s, 3H), 1.99 – 
1.55 (m, 6H), 1.41 (m, 3H), 0.94 (t, J = 7.0, 6H). 13C NMR (100 MHz, CDCl3) δ = 66.1, 
54.1, 35.5, 32.5, 20.8, 20.4, 15.5, 13.9, 13.8, 13.5. HRMS (EI+) calcd. for [C9H19SCl+] 
194.0896; found 194.0887. Colorless liquid, 86.4 mg, 89 % yield. 
(2-chlorocyclohexyl)(methyl)sulfide (4-2p) 
 
1H NMR (700 MHz, CDCl3) δ = 4.09 – 3.93 (m, 1H), 2.77– 2.72 (m, 1H), 2.35 – 2.13 (m, 
5H), 1.83 – 1.60 (m, 3H), 1.51 (dd, J = 13.6, 9.0, 1H), 1.44 – 1.29 (m, 2H). 13C NMR (100 
MHz, CDCl3) δ = 63.3, 51.9, 34.3, 30.6, 23.9, 23.5, 14.9. HRMS (EI+) calcd. for 
[C7H13SCl+] (M+) 164.0427; found 164.0434. Yellow oil, 66.3 mg, 81 % yield. 
(3-chlorobicyclo[2.2.1]heptan-2-yl)(methyl)sulfide (4-2q) 
 
1H NMR (400 MHz, CDCl3) δ = 4.07–  3.99 (m, 1H), 2.57 (t, J = 3.0, 1H), 2.46 (s, 1H), 
2.26 – 2.13 (m, 4H), 2.02 – 1.91 (m, 1H), 1.78 (d, J = 10.4, 1H), 1.75 – 1.62 (m, 1H), 
1.52 – 1.30 (m, 3H). 13C NMR (100 MHz, CDCl3) δ = 68.3, 58.5, 44.3, 43.1, 36.0, 29.1, 
21.7, 14.9. HRMS (EI+) calcd. for [C8H13SCl+] (M+) 176.0427; found 176.0426. Colorless 
oil, 70.4 mg, 80 % yield. 
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3-chloro-4-(methylthio)tetrahydrothiophene 1,1-dioxide (4-2r)  
 
1H NMR (400 MHz, CDCl3) δ = 4.53– 4.48 (m, 1H), 3.85 (dd, J = 13.9, 6.9, 1H), 3.75 (dd, 
J = 13.7, 7.7, 1H), 3.60 (q, J = 7.2, 1H), 3.39 (dd, J = 13.9, 6.4, 1H), 3.15 (dd, J = 13.6, 
7.1, 1H), 2.26 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 58.9, 56.2, 56.1, 50.0, 15.2. 
HRMS (EI+) calcd. for [C13H17O2SCl+] 199.9733; found 199.9729. Yellow liquid, 67.6 mg, 
68 % yield 
2-(methylthio)-1-phenylethanol (4-2s)  
 
1H NMR (400 MHz, CD2Cl2) δ = 7.44 – 7.27 (m, 5H), 4.77 (d, J = 9.0, 1H), 2.94 (s, 1H), 
2.88 (dd, J=13.9, 3.6, 1H), 2.72 (dd, J = 13.8, 9.3, 1H), 2.13 (s, 3H). 13C NMR (100 MHz, 
CD2Cl2) δ = 142.8, 128.3, 127.6, 125.8, 70.9, 44.0, 15.2 HRMS (EI+) calcd. for 
[C9H12OS+] (M+) 168.0609; found 168.0608. Yellow liquid, 62.2 mg, 74 % yield 
1-(4-fluorophenyl)-2-(methylthio)ethanol (4-2t)  
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1H NMR (700 MHz, CD2Cl2) δ = 7.25 (s, 2H), 6.95 (d, J = 6.6, 2H), 4.63 (d, J = 6.8, 1H), 
2.85 (dd, J=13.9, 3.8, 1H), 2.00 (s, 3H). 13C NMR (100 MHz, CDCl3) 13C NMR (100 MHz, 
CD2Cl2) δ = 163.4, 161.0, 138.7, 127.5, 115.3, 70.4, 44.0, 15.2. 19F NMR (376 MHz, 
CD2Cl2) δ = -116.8. HRMS (EI+) calcd. for [C9H11OSF+] (M+) 186.0515; found 186.0519. 
Yellow liquid, 76.2 mg, 82 % yield. 
(2R,3S,4S,5R,6R)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-6-(5-chloro-6-
(methylthio)hexyloxy)tetrahydro-2H-pyran (4-2v)  
 
1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz, cdcl3) δ = 7.39 – 7.10 (m, 20H), 5.04 – 
4.34 (m, 10H), 3.98 (t, J = 9.1, 2H), 3.84 – 3.34 (m, 8H), 2.92 – 2.72 (m, 2H), 2.13 (s, 
3H), 2.01 (dd, J = 9.6, 4.4, 1H), 1.78 – 1.61 (m, 4H). 13C NMR (100 MHz, CDCl3) δ = 
138.8, 138.6, 138.3, 138.1, 137.9, 128.4, 128.0, 127.9, 127.9, 127.8, 127.7, 127.6, 
127.5, 103.6, 97.0, 84.7, 82.2, 82.1, 80.0, 77.9, 77.7, 75.7, 75.1, 75.0, 74.8, 74.7, 73.5, 
73.2, 70.1, 69.7, 68.9, 68.5, 67.9, 61.7, 42.4, 36.5, 29.3, 28.9, 23.1, 16.6. White solid, 
162.0 mg, 46 % yield. 
3-((methylthio)methyl)isobenzofuran-1(3H)-one (4-2w)  
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1H NMR (400 MHz, CDCl3) δ = 7.91 (d, J = 7.6, 1H), 7.71 – 7.65 (m, 1H), 7.61 (d, J = 
7.1, 1H), 7.55 (t, J = 7.5, 1H), 5.64 (t, J = 5.6, 1H), 3.17 (d, J = 110.3, 2H), 2.86 (d, J = 
126.7, 2H), 2.20 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 169.9, 148.6, 134.0, 129.5, 
126.4, 125.7, 122.4, 80.3, 38.4, 17.1. HRMS (EI+) calcd. for [C10H10O2S+] (M+) 194.0402; 
found 194.0395. Colorless liquid, 92.2 mg, 95 % yield. 
(2-chloro-3-phenylpropyl)(phenyl)sulfide (4-3a)  
 
1H NMR (400 MHz, CDCl3) δ = 7.45 – 7.13 (m, 10H), 4.20 – 4.09 (m, 1H), 3.40 – 3.28 
(m, 2H), 3.18 (dd, J = 13.9, 7.8, 1H), 3.01 (dd, J = 14.2, 7.9, 1H). 13C NMR (100 MHz, 
CDCl3) δ = 137.1, 134.9, 130.1, 129.5, 129.2, 128.4, 126.9, 126.8, 61.1, 42.6, 41.3. 
HRMS (EI+) calcd. for [C15H15SCl+] 262.0583; found 262.0590. Yellow liquid, 66.8 mg, 
51 % yield. 
 (2-chloro-3-phenylpropyl)(p-tolyl)sulfide (4-3b)  
 
1H NMR (400 MHz, CDCl3) δ = 7.38 – 7.07 (m, 9H), 4.17 – 4.10 (m, 1H), 3.42 – 3.29 (m, 
2H), 3.15 (dd, J = 13.9, 8.0, 1H), 3.00 (dd, J = 14.3, 8.1, 1H), 2.34 (s, 3H). 13C NMR (100 
MHz, CDCl3) δ = 137.2, 131.5, 131.1, 130.9, 129.9, 129.8, 129.7, 129.6, 128.4, 126.9, 
61.2, 42.5, 42.0, 21.1. HRMS (EI+) calcd. for [C16H17SCl+] (M+) 276.0555; found 
276.0547. Yellow liquid, 89.7 mg, 65 % yield. 
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(4-bromophenyl)(2-chloro-3-phenylpropyl)sulfide (4-3c)  
 
1H NMR (400 MHz, CDCl3) δ = 7.46 – 7.16 (m, 9H), 4.19 – 4.08 (m, 1H), 3.36 – 2.99 (m, 
4H). 13C NMR (100 MHz, CDCl3) δ = 136.9, 134.2, 132.4, 132.3, 131.5, 129.5, 128.5, 
127.1, 120.7, 60.7, 42.8, 41.3. HRMS (EI+) calcd. for [C15H14SClBr+] (M+) 339.9688; 
found 339.9687. Yellow oil, 101.9 mg, 60 % yield. 
(2-chloro-3-phenylpropyl)(4-chlorophenyl)sulfide (4-3d)  
 
1H NMR (400 MHz, CDCl3) δ = 7.41 – 7.09 (m, 9H), 4.16 – 4.09 (m, 1H), 3.38 – 2.93 (m, 
4H). 13C NMR (100 MHz, CDCl3) δ = 136.9, 133.5, 132.9, 131.4, 129.5, 129.3, 128.5, 
127.0, 60.9, 42.7, 41.5. HRMS (EI+) calcd. for [C15H14SCl2+] (M+) 266.1505; found 
296.1517. Yellow liquid, 81.4 mg, 55 % yield. 
(2-chloro-3-(methylsulfonyl)propyl)benzene (4-4)  
 
1H NMR (400 MHz, CDCl3) δ = 7.39 – 7.17 (m, 5H), 4.65- 4.59 (m, 1H), 3.45 – 3.32 (m, 
2H), 3.25 – 3.14 (m, 2H), 3.06 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 135.4, 129.5, 
129 
128.9, 128.8, 127.6, 61.3, 54.9, 44.3, 43.2. HRMS (EI+) calcd. for [C10H13O2SCl+] (M+) 
232.0325; found 232.0323. Colorless oil, 113.6 mg, 98 % yield. 
2-(1-(4-fluorophenyl)-2-(methylthio)ethyl)-1H-pyrrole (4-5)  
 
1H NMR (400 MHz, CD2Cl2) δ = 8.17 (s, 1H), 7.29 – 7.16 (m, 2H), 7.04 (t, J = 8.6, 2H), 
6.68 (s, 1H), 6.11 (d, J = 2.4, 1H), 5.99 (s, 1H), 4.19 (t, J = 7.4, 1H), 3.21 (dd, J = 13.1, 
7.2, 1H), 3.00 (dd, J = 13.1, 7.7, 1H), 2.05 (s, 3H). 13C NMR (100 MHz, CD2Cl2) δ = 
162.9, 160.5, 138.5, 133.5, 129.5, 117.0, 115.3, 108.0, 105.6, 43.8, 40.3, 15.9. 19F NMR 
(376 MHz, CD2Cl2) δ = -116.8. Colorless liquid, 89.7 mg, 65 % yield. 
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5. A 5+1 PROTIC ACID-ASSISTED AZA-PUMMERER 
APPROACH FOR SYNTHESIS OF   4-




Functionalized piperidines are ubiquitous in natural products114 and pharmaceuticals 
(Figure 9).115 Despite an extensive literature on piperidine syntheses,116 there are still 
demands for more efficient syntheses. The common strategies for the synthesis of 
piperidine skeletons involve intra-117 and intermolecular118 cyclization reactions, ring 
expansion processes119 and reduction of pyridines.120 Cycloaddition  is the predominant 
approach. This is achieved either by a nucleophilic substitution process (Scheme 
9a),116c, 121 transition metal catalysis (Scheme 9b),116a, b, 122 or an electrophile- or radical-
induced cyclization (Scheme 9c).123 The use of designed or protected substrates and 
expensive transition metals limit the application of some of these methods. Another 
notable method for obtaining 4-chloropiperidines is through the aza-Prins cyclization 
method (Scheme 1e).54b, 118a, 124 This method usually requires transition metal or Lewis 
acid catalysis. In our search for applications of the newly formulated HCl/DMPU,9, 105 a 
highly concentrated, bench stable, readily prepared and easily dispensable anhydrous 
source of HCl, we observed the activation of DMSO. Activation of dimethyl sulfoxide by 
electrophiles125 has been widely reported and has led to application of DMSO as a viable 
synthon,101b as noted by the increased use of DMSO as a one carbon source in the 
160 
recent literature (Scheme 9d).94c, 126 In this chapter, we describe an application of our 
HCl/DMPU-mediated DMSO activation to prepare 4-chloropiperidines. 
Figure 9. Examples of piperidine-containing natural products and drug molecules 
 
Despite the tremendous progress made in alkene amino cyclization reactions,117, 124o, 127 
there are still limitations in the substrate scope for intramolecular construction of 
piperidines. We wanted to avoid the use of toxic formaldehyde as a one carbon synthon. 
To address these limitations, we surmised one possible solution would be to exploit 
formation of (thiomethyl)methyl carbenium ion from DMSO in the presence of 
homoallylic amines (Scheme 9e).128 The thiocarbenium ion generation could arise from a 
Pummerer fragmentation through the interaction of the sulfoxide with an electrophile. 
Such activations are common in activated, high-molecular weight sulfoxides.129 
However, the use of protic acid activation of DMSO has not been widely explored.100b, 130 
We envisioned that reaction of the thiocarbenium ion with a homoallylic amine might 
initiate an intramolecular cyclization to form a piperidine ring. Specifically, tandem 
electrophilic capture of the DMSO-derived (thiomethyl)methyl carbenium ion by the 
homoallylic amine followed by intramolecular reaction of the pendant vinyl system with 
subsequent counterion trapping of the resulting electrophilic center could afford access 
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to 4-substituted piperidines. Such an approach would provide a nice compliment to 
current halo-piperidation techniques.118a, 124a, 131 





5.2. Results and discussion 
Table 10. Reaction condition optimization 
 
Entry Solvent HCl source Conc. Conv. /%a 
1 DCE HClDMPU 1.0 64 
2 CH3CN HClDMPU 1.0 22 
3 CH3NO3 HClDMPU 1.0 30 
4 EtOAc HClDMPU 1.0 90 
5 DMSO HClDMPU 1.0 18 
6 EtOAc HClDMPU 0.5 89 
7 EtOAc HClDMPU 0.2 99 
8 EtOAc HCl, Et2O 0.2 32 (98)b 
9 EtOAc HCl, 2-propanol 0.2 99c 
10 EtOAc HCl, dioxane 0.2 65 (94)b 
11 EtOAc HCl, AcOH 0.2 99c 
12 EtOAc HCl, H2O 0.2 29 (65)b 
13 EtOAc CH3COCl/EtOH 0.2 99 
14 EtOAc TMSCl/MeOH 0.2 95 
        aDetermined by GC-MS with dodecane as the internal standard. b 24 h, c combined 
with thiolated side product.   
We began our investigation using the homoallylic amine 5-1a, HCl•DMPU (2.4 equiv) 
and DMSO (2.4 equiv) in DCE at 65 oC (Table 10). We were pleased to observe that the 
163 
desired cyclized product 5-2a was obtained in a decent yield. A solvent screening (Table 
10, entries 1-5) indicated a better conversion in ethyl acetate, albeit with poor selectivity. 
The reaction progress appeared to be retarded by more polar solvents, possibly due to 
solvolysis. Reaction concentration played an important role in selectivity (Table 10, 
entries 6 and 7) as lower concentration favored the piperidine formation. Longer reaction 
times led to complete conversion (Table 10, entry 8). We also investigated other HCl 
sources. As expected, the lower concentration sources were sluggish (Table 10, entries 
9 and 11) while the more concentrated sources gave appreciable conversions with lower 
ratios of the desired product (Table 10, entries 10 and 12). Use of aqueous HCl gave a 
dismal outcome; however, the conversions with in situ generated HCl (Table 10, entries 
14 and 15) proceeded with comparable selectivity to the ready-made HCl•DMPU 
reagent. Encouraged by these results, we examined the substrate scope of this new 
cyclization reaction with the optimum condition (Table 11).    
We first examined the scope of homoallylic anilines. The study revealed that there was 
broad tolerance of substituents with diverse electronic properties on all positions on the 
aromatic ring giving good to excellent yields. An array of para-substituted anilines 
containing groups such as methyl (5-2b), halo (5-2d, 5-2e, 5-2f), trifluoromethyl (5-2j), 
methoxy (5-2k), cyano (5-2l), trifluoromethoxy (5-2m), nitro (5-2n), phenyl (5-2r) and 
acetyl (5-2t) all proceeded in excellent yields. Single crystal X-ray structure of the 4-
nitrophenyl derivative (5-2n), was obtained showing the chlorine atom locked in the axial 
position (Figure 10). The inclusion of similar substituents at the ortho (5-2i, 5-2o, 5-2s) 
and meta (5-2c, 5-2g, 5-2h, 5-2q) positions did not affect the yields. The method 
displayed good functional group tolerance to groups like nitrile (5-2l), ester (5-2w), 
ethers (5-2k, 5-2m, 5-2v) and ketones (5-2t, 5-2u). Interestingly, homoallylic 
sulfonamides (5-2aa, 5-2ab, 5-2ac) underwent the transformation in excellent yields. 
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Table 11. Substrate scope for synthesis of 4-chloropiperidines  
 
Heteroaromatic amines containing benzodioxole (5-2v), thiophene (5-2w), pyridine (5-
2x, 5-2y) and pyrazine (5-2z) moieties also gave desired cyclization products in good 
yields. While meta-polysubstitution (5-2p) was highly selective resulting to a yield of 
90%, the trisubstituted substrate (5-2ai) gave an inseparable 3:2 mixture of piperidine 
and pyrrolidine respectively. The scope was extended to aliphatic amines. Though 
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strongly basic, we were delighted to observe satisfactory product yields of 51-64%. 
Benzyl (5-2ag, 5-2ah) and longer aliphatic chain (5-2ad, 5-2ae, 5-2af) substrates were 
also tolerated. 
Figure 10. ORTEP representation of (2n) with thermal ellipsoids shown at the 50% 
probability level 
 
Unfortunately, the method was unsuccessful with the hydrazide (5-2aj), hydroxylamine 
(5-2ak) and indole (5-2al) substrates likely due to substrate intolerance and product 
instability (Figure 11).  
Figure 11. Failed substrates 
 
Next, we investigated the scope of the alkene chain (Table 12). Both terminal and 
internal substituted alkenes afforded desired products. The disubstituted alkenes (5-5-
3a, 5-3b, 5-3c, 5-3d) furnished the desired cyclized products (5-4a, 5-4b, 5-4c, 5-4d) in 
good yields of 81%, 84%, 53% and 65% respectively. The major diastereomer, 5-4d, 
exhibited an anti-stereochemistry. The sterically hindered homoallylic amine derivative of 
nopol (3c) underwent the cyclization in a modest 53% yield. Good yields and 
diastereoselectivity were achieved for the trans-internal alkene. Due to steric demands, 
the 1,1,2-trisubstituted alkene substrate (5-3e) failed to achieve desired outcomes. 
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Rather it formed the kinetically favored pyrrolidine product in 64% yield. Also, the cyclic 
alkene substrate (5-3f) was unsuccessful probably because of ring strain barrier 
associated with its formation.  
Table 12. Scope for synthesis of 4-chloropiperidines 
 
To demonstrate the practicality of the method, a 10 mmol reaction (Scheme 10, eq 1) of 
5-1a was performed without any further modifications. We were gratified to find that 
desired product 5-2a was obtained in high yield. To probe the mechanism of the 
process, a deuterium labeling experiment using deuterated DMSO was performed. High 
167 
deuterium incorporation of over 99% was observed for the resulting piperidine (Scheme 
10, eq 2). This indicates that the extra carbon arises from DMSO. Zhong and co-
workers132 reported that DMSO can serve as a formaldehyde surrogate. It is however, 
inconclusive that it is the case here because as earlier referenced, DMSO can equally 
serve as a one-carbon source.  Given the abundance of chloride ion during the reaction, 
the in-situ generation of chloromethyl methyl sulfide (IIb) as an intermediate is possible. 
Indeed, reaction of the starting amine with commercially available chloromethyl methyl 
sulfide led to the formation of 5-2a in 64% yield (Scheme 10, eq 3). Finally, to seek 
insight as to the intermediacy of an iminium ion prior to cyclization, we performed the 
reaction with tertiary amine 5-7 and observed no cyclization to give 5-2a. Rather the 
chlorothiolated product 5-810 was formed in 67% (Scheme 10, eq 4). 
Scheme 10. Gram scale reaction and mechanistic study 
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Based on the above results, a plausible mechanism is proposed (Scheme 11). 
Electrophilic activation of DMSO by HCl generates sulfonium salt I, which undergoes 
base-assisted elimination of water to generate (thiomethyl)methyl carbenium ion IIa. 
Interchangeable formation of chloromethyl methyl sulfide (IIb) may also be operative. 
IIa/b reacts with the starting amine to ultimately generate iminium ion V from ammonium 
salt IV via proton transfer (P.T.) and elimination of methyl mercaptan. A 6-endo-trig 
cyclization133 followed by nucleophilic addition of chloride ion gives the desired product. 




In summary, we have developed a convenient protic acid-catalyzed formation of 
(thiomethyl)methyl carbenium ion from DMSO under mild conditions. In the presence of 
homoallylic amines, the in situ-generated species reacts in aza-Pummerer fashion to 
generate an iminium ion intermediate that cyclizes to form 4-chloropiperidines in good 
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yield. The method is applicable to both aromatic and aliphatic amines. The use of 
HCl•DMPU as protic acid, non-nucleophilic base and chloride source provides an 
environmentally benign method for piperidine formation. The reaction has a broad 
substrate scope and is scalable. 
 
5.4. Experimental 
5.4.1. General  
1H and 13C NMR spectra were recorded either at 400 MHz or 500 MHz, and 101 MHz 
using CDCl3 or CD2Cl2 as a solvent. The chemical shifts are reported in δ (ppm) values 
(1H and 13C NMR relative to CHCl3, δ 7.26 ppm for 1H NMR and δ 77.0 ppm for 13C 
NMR, multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), p 
(pentet), h (hextet), m (multiplet) and br (broad). Coupling constants (J), are reported in 
Hertz (Hz). The HRMS data was obtained from an Agilent Technologies QTOF 
spectrometer. All reagents and solvents were employed without further purification. The 
products were purified using a commercial flash chromatography system. TLC was 
developed on silica gel 60 F254 aluminum sheets.  
5.4.2.General procedure for preparing homoallylic amines, 1 and 3134. 
To a round bottomed flask equipped with a stirring bar was charged with aryl or 
alkylamine 5-1 or 5-3 (1.2 mmol, 1.2 equiv), K2CO3 (2 mmol, 2 equiv) and dry DMF (3 
mL). Homoallyl bromide (1 mmol, 1 equiv) was slowly added to the mixture and heated 
to 110 oC. The progress of the reaction was monitored by GC-MS and/or TLC. Upon 
completion, the reaction mixture was cooled to room temperature and water (10 mL) and 
extracted with ethyl acetate (3 X 10 mL). The combined organic layers were then dried 
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over anhydrous Na2SO4, filtered, concentrated and eventually purified silica gel column 
chromatography with hexanes/ethyl acetate or petroleum ether/ethyl acetate as eluent. 
5.4.3. Procedure for synthesis of 4-chloropiperidines, 5-2 and 5-4. 
 
A glass vial equipped with a screw cap and a stirring bar was charged with alkene 5-1 
(0.5 mmol). Then ethyl acetate was added (2.5 mL) followed by DMSO (2.4 mmol) and 
HCl/DMPU (102 µL, 2.4 mmol). The reaction mixture was stirred at 65 oC and the 
progress of the reaction was monitored by GC-MS or TLC. Upon completion, the 
reaction mixture was quenched with water and extracted with DCM. The combined 
organic layers were then dried over anhydrous Na2SO4, filtered and solvent evaporated. 
The crude product was purified by silica gel column chromatography (hexanes/ethyl 
acetate). 




1H NMR (400 MHz, CDCl3) δ 7.19 (t, J = 7.9 Hz, 2H), 6.72 (t, J = 7.3 Hz, 1H), 6.63 (d, J 
= 7.8 Hz, 2H), 5.85– 5.79 (m, 1H), 5.21 – 5.07 (m, 2H), 3.63 (s, 1H), 3.20 (t, J = 6.7 Hz, 
2H), 2.40 (q, J = 6.7 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ  148.4, 136.0, 129.4, 117.6, 





1H NMR (400 MHz, CDCl3) δ 7.00 (d, J = 8.0 Hz, 2H), 6.56 (d, J = 8.0 Hz, 2H), 5.87– 
5.78 (m, 1H), 5.17 – 5.10 (m, 2H), 3.52 (s, 1H), 3.17 (t, J = 6.7 Hz, 2H), 2.38 (q, J = 6.7 
Hz, 2H), 2.25 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 146.1, 136.0, 129.8, 126.68, 117.1, 




1H NMR (400 MHz, CDCl3) δ 7.07 (t, J = 7.9 Hz, 1H), 6.53 (d, J = 7.6 Hz, 1H), 6.43 (d, J 
= 7.7 Hz, 2H), 5.86 – 5.78 (m, 1H), 5.17 – 5.10 (m, 2H), 3.60 (s, 1H), 3.18 (t, J = 6.7 Hz, 
2H), 2.42 – 2.32 (m, 2H), 2.28 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 148.2, 138.9, 





1H NMR (400 MHz, CDCl3) δ 6.88 (t, J = 8.8 Hz, 2H), 6.54 (dd, J = 9.0, 4.4 Hz, 2H), 5.85 
– 5.76 (m, 1H), 5.17 – 5.10 (m, 2H), 3.54 (s, 1H), 3.14 (t, J = 6.7 Hz, 2H), 2.37 (q, J = 6.7 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 156.8, 144.6, 135.7, 117.2, 115.7, 115.6, 113.7, 




1H NMR (500 MHz, CDCl3) δ 7.11(d, J = 7.8, 2H), 6.53 (d, J = 7.9, 2H), 5.81 – 5.77 (m, 
1H), 5.15 – 5.10 (m, 2H), 3.66 (s, 1H), 3.14 (t, J = 6.4 Hz, 2H), 2.37 (q, J = 6.7, 2H). 13C 




1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.8 Hz, 2H), 6.60 (d, J = 8.8 Hz, 2H), 5.97 – 
5.88 (m, 1H), 5.29 – 5.23 (m, 2H), 3.80 (s, 1H), 3.27 (t, J = 6.7 Hz, 2H), 2.50 (q, J = 6.7 






1H NMR (500 MHz, CDCl3) δ 7.02 (d, J = 7.7 Hz, 1H), 6.99 – 6.92 (m, 1H), 6.88 (t, J = 
8.0 Hz, 1H), 6.56 (dd, J = 8.2, 2.2 Hz, 1H), 5.82 (ddt, J = 17.0, 10.1, 6.8 Hz, 1H), 5.29 – 
4.97 (m, 2H), 3.69 (s, 1H), 3.16 (dd, J = 11.9, 6.4 Hz, 2H), 2.39 (dt, J = 7.9, 6.1 Hz, 2H). 





1H NMR (500 MHz, CDCl3) δ 7.02 (t, J = 8.0 Hz, 1H), 6.81 (d, J = 7.1 Hz, 1H), 6.75 (d, J 
= 1.7 Hz, 1H), 6.52 (dd, J = 8.2, 2.1 Hz, 1H), 5.75-5.63 (m, 1H), 5.15 (t, J = 13.2 Hz, 2H), 
3.74 (s, 1H), 3.17 (dd, J = 12.2, 6.4 Hz, 2H), 2.39 (q, J = 6.7 Hz, 2H). 13C NMR (126 
MHz, CDCl3) δ 149.5, 135.4, 130.5, 123.3, 120.0, 117.4, 115.3, 111.6, 42.6, 33.4. 
 
N-(but-3-en-1-yl)-2-iodo-4-methylaniline (5-1i)  
 
1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 1.7 Hz, 1H), 7.02 (dd, J = 8.2, 1.7 Hz, 1H), 
6.48 (d, J = 8.2 Hz, 1H), 5.85 (ddt, J = 17.1, 10.2, 6.9 Hz, 1H), 5.23 – 5.10 (m, 2H), 4.05 
174 
(s, 1H), 3.20 (t, J = 6.7 Hz, 2H), 2.43 (q, J = 6.8 Hz, 2H), 2.21 (s, 3H). 13C NMR (100 




1H NMR (400 MHz, CDCl3) δ 7.45 - 7.30 (m, 2H), 6.68 (d, J = 8.3 Hz, 2H), 6.59 (d, J = 
8.5 Hz, 2H), 5.81 (dd, J = 17.1, 10.2 Hz, 2H), 5.14 (dd, J = 12.7, 11.0 Hz, 3H), 3.97 (s, 
3H), 3.21 (t, J = 6.7 Hz, 3H), 2.39 (d, J = 6.7 Hz, 3H). 13C NMR (100 MHz, cdcl3) δ 150.4, 




1H NMR (400 MHz, CDCl3) δ 6.80 (d, J = 8.9 Hz, 2H), 6.60 (d, J = 8.9 Hz, 2H), 5.87 – 
5.80 (m, 1H), 5.19 – 5.07 (m, 2H), 3.75 (s, 3H), 3.32 (s, 1H), 3.15 (t, J = 6.7 Hz, 2H), 
2.38 (q, J = 6.7 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ δ 152.2, 142.6, 136.0, 117.1, 





1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.8 Hz, 2H), 6.55 (d, J = 8.8 Hz, 2H), 5.80 (ddt, 
J = 17.1, 10.2, 6.8 Hz, 1H), 5.20 – 5.08 (m, 2H), 4.24 (s, 1H), 3.22 (t, J = 6.7 Hz, 2H), 
2.39 (q, J = 6.7, 2H). 13C NMR (100 MHz, CDCl3) δ 151.2, 135.0, 133.7, 120.5, 117.7, 




1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 8.9 Hz, 2H), 6.60 (d, J = 9.0 Hz, 2H), 5.87 – 
5.78 (m, 1H), 5.25 – 5.14 (m, 2H), 3.78 (s, 1H), 3.21 (t, J = 6.7 Hz, 2H), 2.43 (q, J = 6.7 
Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 146.9, 140.3, 135.4, 124.5, 122.3, 121.9, 119.4, 
117.2, 116.8, 112.9, 42.8, 33.4. 19F NMR (376 MHz, CDCl3) δ -58.31. 
 
N-(but-3-en-1-yl)-4-nitroaniline (5-1n) 
                                             
1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 9.2 Hz, 2H), 6.53 (d, J = 9.2 Hz, 2H), 5.87– 
5.77 (m, 1H), 5.26 – 5.11 (m, 2H), 4.50 (s, 1H), 3.29 (dd, J = 12.1, 6.6 Hz, 2H), 2.43 (q, J 
= 6.7 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 153.3, 149.7, 138.2, 134.9, 126.6, 118.2, 





1H NMR (400 MHz, CDCl3) δ 7.79 - 7.19 (m, 2H), 6.95 - 6.62 (m, 2H), 5.92-5.80 (m, 1H), 
5.69 - 5.02 (m, 2H), 4.55 (s, 1H), 3.39 (t, J = 6.4 Hz, 2H), 2.59 (ddd, J = 6.7, 6.2, 1.2 Hz, 
2H). 13C NMR (100 MHz, CDCl3) δ 145.8, 135.2, 133.2, 126.8, 126.7, 124.0, 117.7, 




1H NMR (400 MHz, CDCl3) δ 7.04 (s, 1H), 6.83 (s, 2H), 5.72 (td, J = 16.8, 6.6 Hz, 1H), 
5.16 - 5.03 (m, 2H), 4.01 (s, 1H), 3.14 (dd, J = 12.1, 6.3 Hz, 2H), 2.33 (q, J = 6.7 Hz, 2H), 
1.45 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 148.3, 134.5, 124.5, 121.8, 117.5, 111.4, 





1H NMR (400 MHz, CDCl3) δ 7.30 (dd, J = 9.2, 6.6 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 
6.84 (s, 1H), 6.78 (d, J = 8.2 Hz, 1H), 5.87 (ddt, J = 17.0, 10.1, 6.8 Hz, 1H), 5.44 – 4.88 
(m, 2H), 3.91 (s, 1H), 3.26 (s, 2H), 2.57 – 2.29 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 
148.4, 135.4, 131.7, 131.4, 129.6, 125.7, 123.0, 117.5, 115.8, 113.7, 113.7, 108.9, 108.9, 




1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 7.8 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.27 (t, J 
= 7.4 Hz, 2H), 7.20 – 7.10 (m, 1H), 6.56 (d, J = 8.4 Hz, 2H), 5.86 – 5.61 (m, 1H), 5.03 (t, 
J = 14.5 Hz, 2H), 3.63 (s, 1H), 3.11 (t, J = 6.7 Hz, 2H), 2.29 (q, J = 6.6 Hz, 2H). 13C NMR 





1H NMR (500 MHz, CDCl3) δ 7.48 – 7.31 (m, 5H), 7.28 – 7.21 (m, 1H), 7.10 (d, J = 7.4 
Hz, 1H), 6.77 (t, J = 7.4 Hz, 1H), 6.73 – 6.68 (m, 1H), 5.94 – 5.50 (m, 1H), 5.00 (dd, J = 
178 
8.6, 6.5 Hz, 2H), 3.99 (s, 1H), 3.18 (dd, J = 11.8, 6.4 Hz, 2H), 2.32 (q, J = 6.7 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 145.0, 139.4, 135.6, 130.1, 129.4, 128.8, 128.7, 127.7, 




1H NMR (500 MHz, CDCl3) δ = 7.84 (d, J=8.8, 2H), 6.60 – 6.50 (m, 2H), 5.78-5.66 (m, 
1H), 5.21 - 5.08 (m, 2H), 4.21 (s, 1H), 3.27 (dd, J=12.2, 6.6, 2H), 2.50 (d, J=6.9, 2H), 
2.42 (dd, J=13.5, 6.8, 1H). 13C NMR (126 MHz, CDCl3) δ 152.0, 135.1, 130.8, 117.6, 
111.4, 42.1, 33.4, 26.0.  
 
(3-(but-3-en-1-ylamino)phenyl)(phenyl)methanone (5-1u) 
                                                                                     
1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 7.7 Hz, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.47 (t, J 
= 7.5 Hz, 2H), 7.29 - 7.24 (m, 1H), 7.06 (d, J = 6.5 Hz, 2H), 6.82 (d, J = 8.3 Hz, 1H), 
5.77-5.66 (m, 1H), 5.14 (t, J = 13.2 Hz, 2H), 3.81 (s, 1H), 3.22 (t, J = 6.7 Hz, 2H), 2.46 - 
2.31 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 197.2, 148.2, 138.6, 137.9, 135.5, 132.2, 




            
1H NMR (500 MHz, CDCl3) δ 6.67 (d, J = 8.3 Hz, 1H), 6.26 (s, 1H), 6.07 (d, J = 8.3 Hz, 
1H), 5.97 - 5.74 (m, 3H), 5.10-5.01 (m, 2H), 3.45 (s, 1H), 3.13 (td, J = 6.7, 1.4 Hz, 2H), 
2.44 - 2.31 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 148.3, 144.1, 139.6, 135.7, 117.1, 
108.6, 104.5, 100.5, 96.1, 43.8, 33.6. 
 
methyl 3-(but-3-en-1-ylamino)thiophene-2-carboxylate (5-1w) 
 
1H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 5.5 Hz, 1H), 6.76 (s, 1H), 6.63 (d, J = 5.5 Hz, 
1H), 5.86 –5.79 (m, 1H), 5.18 – 5.11 (m, 2H), 3.81 (s, 3H), 3.34 (d, J = 2.7 Hz, 2H), 2.50 
– 2.28 (m, 2H)..  13C NMR (100 MHz, CDCl3) δ 165.4, 156.1, 135.1, 132.2, 117.4, 116.2, 




1H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H), 7.09 (d, J = 8.6 Hz, 1H), 6.87 (d, J = 8.6, 1H), 
5.76-5.64 (m, 1H), 5.16 (dd, J = 13.3, 6.3 Hz, 2H), 3.74 (s, 1H), 3.18 (dd, J = 12.5, 6.4 
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Hz, 2H), 2.40 (q, J = 6.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 143.2, 139.0, 135.0, 




1H NMR (500 MHz, CDCl3) δ 8.03 (s, 1H), 7.36 (d, J = 8.8, 1H), 6.33 (d, J = 8.9 Hz, 1H), 
5.93 – 5.69 (m, 1H), 5.34 – 4.99 (m, 2H), 4.53 (s, 1H), 3.41 – 3.27 (m, 2H), 2.38 (dt, J = 
6.6, 5.5 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 143.4, 138.8, 135.1, 134.5, 124.1, 122.3, 




1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 1.2 Hz, 1H), 7.64 (d, J = 1.2 Hz, 1H), 5.76-5.65 
(m, 1H), 5.32 – 4.98 (m, 2H), 4.68 (s, 1H), 3.40 (dd, J = 12.4, 6.6 Hz, 2H), 2.40 (q, J = 
6.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 153.3, 141.2, 136.0, 135.0, 129.9, 117.7, 





1H NMR (500 MHz, CDCl3) δ 6.67 (dd, J = 8.3, 1.6 Hz, 1H), 6.26 (t, J = 1.8 Hz, 1H), 6.06 
(ddd, J = 11.6, 6.8, 4.8 Hz, 1H), 5.92 – 5.77 (m, 3H), 5.15-5.05 (m, 2H), 3.69 - 3.21 (m, 
1H), 3.13 (td, J = 6.7, 1.4 Hz, 2H), 2.49 - 2.25 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
148.3, 144.1, 139.6, 135.7, 117.1, 108.6, 104.5, 100.5, 96.1, 43.8, 33.6. 
N-(but-3-en-1-yl)-4-methoxybenzenesulfonamide (5-1ab) 
 
1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 5.72 - 
5.39 (m, 1H), 5.13 – 4.78 (m, 2H), 4.65 (d, J = 6.0 Hz, 1H), 3.80 (d, J = 0.6 Hz, 3H), 3.07 
– 2.71 (m, 2H), 2.13 (q, J = 6.8 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 162.8, 134.1, 
131.4, 129.1, 117.9, 114.2, 55.6, 42.0, 33.5. 
 
4-bromo-N-(but-3-en-1-yl)benzenesulfonamide (5-1ac) 
                                                                                 
1H NMR (500 MHz, CDCl3) δ 7.77 - 7.69 (m, 2H), 7.68 - 7.62 (m, 2H), 5.58-5.46 (m, 1H), 
5.16 - 4.95 (m, 2H), 4.90 (s, 1H), 3.03 (dd, J = 12.9, 6.7 Hz, 2H), 2.22 (qt, J = 6.8, 1.3 Hz, 





1H NMR (400 MHz, CDCl3) δ 5.78 (m, J = 13.7, 10.2, 5.1 Hz, 1H), 5.18 - 4.93 (m, 2H), 
2.66 (t, J = 6.9 Hz, 2H), 2.49 (d, J = 6.2 Hz, 2H), 2.32 - 2.13 (m, 2H), 1.52 – 1.36 (m, 1H), 
1.35 - 1.20 (m, 7H), 0.88 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 136.6, 116.1, 53.1, 49.2, 




1H NMR (400 MHz, CDCl3) δ 7.56 – 7.33 (m, 5H), 5.99 – 5.90 (m, 1H), 5.30 – 5.15 (m, 
2H), 3.13 – 3.05 (m, 2H), 3.03 – 2.97 (m, 2H), 2.90 (t, J = 6.9 Hz, 2H), 2.44 (q, J = 6.9 
Hz, 2H), 1.31 (s, 1H).. 13C NMR (100 MHz, CDCl3) δ 140.2, 136.5, 128.8, 128.5, 126.2, 




1H NMR (400 MHz, CDCl3) δ 7.21 (d, J = 8.5 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H), 5.79 – 
5.67 (m, 1H), 5.25 – 4.97 (m, 2H), 3.87 (s, 2H), 2.98 – 2.90 (m, 2H), 2.86 – 2.74 (m, 2H), 
183 
2.32 (q, J = 6.9 Hz, 2H), 1.83 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 158.1, 136.4, 132.1, 




1H NMR (400 MHz, CDCl3) δ = 7.39 – 7.19 (m, 5H), 5.84 – 5.74 (m, 1H), 5.16 – 4.98 (m, 
2H), 3.79 (s, 2H), 2.70 (t, J=6.8, 2H), 2.28 (dt, J=6.9, 6.2, 2H), 1.29 (s, 1H). 13C NMR 




1H NMR (400 MHz, CDCl3) δ 8.15 – 6.33 (m, 5H), 5.69 – 5.58 (m, 1H), 5.31 – 4.69 (m, 
2H), 3.76 (q, J = 6.6 Hz, 1H), 2.72 – 2.36 (m, 2H), 2.29 – 2.07 (m, 2H), 1.34 (d, J = 6.6 
Hz, 3H), 1.27 (s, 1H).  13C NMR (100 MHz, CDCl3) δ 145.7, 136.5, 128.4, 126.8, 126.5, 





1H NMR (400 MHz, CDCl3) δ 7.18 (t, J = 7.9 Hz, 2H), 6.70 (t, J = 7.3 Hz, 1H), 6.61 (d, J 
= 8.1 Hz, 2H), 5.54 -5.41 (m, 1H), 5.50 - 5.37 (m, 1H), 4.13 (s, 1H), 3.65 (s, 1H), 3.13 (t, 
J = 6.7 Hz, 2H), 2.31 (q, J = 6.7 Hz, 2H), 1.70 (d, J = 6.0 Hz, 3H). 13C NMR (100 MHz, 




1H NMR (500 MHz, CDCl3) δ 7.26 - 7.17 (m, 2H), 6.75 (td, J = 7.4, 1.0 Hz, 1H), 6.71 - 
6.58 (m, 2H), 5.75 - 5.63 (m, 1H), 5.55 (d, J = 1.6 Hz, 1H), 3.77 (s, 1H), 3.41 (t, J = 6.5 
Hz, 2H), 2.74 (t, J = 6.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 147.6, 131.3, 129.3, 




1H NMR (400 MHz, CDCl3) δ 7.25 – 7.11 (m, 2H), 6.72 (tt, J = 7.4, 1.0 Hz, 1H), 6.65 – 
6.55 (m, 2H), 5.37 (dt, J = 4.2, 1.3 Hz, 1H), 3.66 (s, 1H), 3.27 – 2.93 (m, 2H), 2.41 (dt, J 
= 8.6, 5.6 Hz, 1H), 2.36 – 2.24 (m, 4H), 2.17 – 1.99 (m, 2H), 1.41 – 1.22 (m, 5H), 0.93 – 
0.81 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 148.4, 145.6, 129.2, 118.7, 117.2, 112.9, 




                
1H NMR (400 MHz, CDCl3) δ 7.18 (t, J = 7.9 Hz, 2H), 6.70 (t, J = 7.3 Hz, 1H), 6.61 (d, J 
= 8.1 Hz, 2H), 5.54-5.44  (m, 1H), 5.50 - 5.37 (m, 1H), 3.65 (s, 1H), 3.13 (t, J = 6.7 Hz, 
2H), 2.31 (q, J = 6.7 Hz, 2H), 1.70 (d, J = 6.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 




1H NMR (400 MHz, CDCl3) δ 7.30 (t, J = 7.7 Hz, 2H), 6.82 (t, J = 7.3 Hz, 1H), 6.74 (d, J 
= 8.0 Hz, 2H), 5.28 (t, J = 7.2 Hz, 1H), 3.76 (s, 1H), 3.24 (t, J = 6.9 Hz, 2H), 2.44 (d, J = 
7.0 Hz, 2H), 1.86 (s, 3H), 1.77 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 148.5, 134.4, 129.3, 




1H NMR (400 MHz, CDCl3) δ 7.23 (t, J = 8.0 Hz, 2H), 6.92 (d, J = 8.0 Hz, 2H), 6.82 (t, J 
= 7.3 Hz, 1H), 4.25 – 4.14 (m, 1H), 3.54 – 3.45 (m, 2H), 3.07 – 2.97 (m, 2H), 2.25 – 2.15 
186 
(m, 2H), 2.03 – 1.92 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 151.1, 129.2, 119.8, 116.6, 
57.2, 47.5, 35.1.  HRMS (EI+) calcd. for [C11H14NCl] (MH+) 196.1044; found 196.1041. 




1H NMR (400 MHz, CDCl3) δ = 7.05 (d, J=7.7, 2H), 6.83 (d, J=7.5, 2H), 4.16 (bs, 1H), 
3.42 – 3.44  (m, 2H), 2.99 – 2.95 (m, 2H), 2.29 – 2.12 (m, 5H), 2.00 – 1.98  (m, 2H). 13C 
NMR (100 MHz, CDCl3) δ 149.0, 129.6, 129.3, 116.9, 57.1, 48.1, 35.2, 20.4. HRMS (EI+) 





1H NMR (400 MHz, CDCl3) δ 7.16 (t, J = 7.7 Hz, 1H), 6.76 (d, J = 8.4 Hz, 2H), 6.70 (d, J 
= 7.4 Hz, 1H), 4.23 – 4.17 (m, 1H), 3.55 – 3.47 (m, 2H), 3.09 – 2.99 (m, 2H), 2.32 (s, 3H), 
2.26 – 2.17 (m, 2H), 2.06 – 1.95 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 151.1, 138.9, 
129.0, 120.8, 117.5, 113.7, 57.2, 47.7, 35.1, 21.8. HRMS (EI+) calcd. for [C12H17NCl] 





1H NMR (400 MHz, CDCl3) δ 7.01 – 6.84 (m, 4H), 4.19 (tt, J = 8.0, 3.9 Hz, 1H), 3.45 – 
3.31 (m, 2H), 3.02 – 2.93 (m, 2H), 2.22 (dtd, J = 10.4, 7.0, 3.6 Hz, 2H), 2.09 – 1.95 (m, 
2H). 13C NMR (100 MHz, CDCl3) δ 158.3, 155.9, 147.7, 118.4, 115.5, 115.3, 56.7, 48.3, 
35.0. 19F NMR (376 MHz, CDCl3) δ = -124.31 (s, 1H). HRMS (EI+) calcd. for 




1H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 9.0 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 4.21 (tt, J 
= 7.6, 3.7 Hz, 1H), 3.52 – 3.35 (m, 2H), 3.13 – 2.97 (m, 2H), 2.27 – 2.11 (m, 2H), 2.06 – 
1.92 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 149.6, 129.0, 124.6, 117.7, 56.8, 47.4, 34.8. 
HRMS (EI+) calcd. for [C11H14NCl2] (MH+) 230.0498; found 230.0496. Colorless oil, 





1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 9.0 Hz, 2H), 6.80 (d, J = 9.0 Hz, 2H), 4.21 (tt, J 
= 7.8, 3.9 Hz, 1H), 3.51 – 3.39 (m, 2H), 3.12 – 2.94 (m, 2H), 2.20 (dtd, J = 10.5, 7.0, 3.6 
Hz, 2H), 2.06 – 1.94 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 150.0, 131.9, 129.1, 118.1, 
56.8, 47.2, 34.7. HRMS (EI+) calcd. for [C11H14NBrCl] (MH+) 273.9993; found 273.9989. 




1H NMR (400 MHz, CDCl3) δ 7.25 – 7.23 (m, 1H), 7.18 – 7.13 (m, 1H), 6.98 – 6.93 (m, 
1H), 6.87 (ddd, J = 8.4, 2.4, 0.8 Hz, 1H), 4.21 (tt, J = 7.8, 3.8 Hz, 1H), 3.53 – 3.44 (m, 
2H), 3.12 – 3.01 (m, 2H), 2.18 (ddd, J = 13.1, 6.8, 3.3 Hz, 2H), 2.03 – 1.92 (m, 2H). 13C 
NMR (100 MHz, CDCl3 δ 152.1, 130.5, 128.4, 125.2, 115.6, 95.2, 56.8, 46.9, 34.7. 
HRMS (EI+) calcd. for [C11H13ClIN] (M+) 320.9781; found 320.9775. Colorless oil, 112.3 





1H NMR (400 MHz, CDCl3) δ 7.11 (t, J=8.1, 1H), 7.05 (t, J=2.1, 1H), 6.96 (ddd, J=7.8, 
1.8, 0.8, 1H), 6.87 – 6.81 (m, 1H), 4.22 (tt, J=7.8, 3.8, 1H), 3.57 – 3.45 (m, 2H), 3.15 – 
3.04 (m, 2H), 2.25 – 2.15 (m, 2H), 2.05 – 1.93 (m,2H). 13C NMR (100 MHz CDCl3) δ 
152.2, 130.4, 123.2, 122.2, 119.1, 114.8, 56.8, 46.8, 34.6. HRMS (EI+) calcd. for 




1H NMR (400 MHz, CDCl3) δ  7.67 (s, 1H), 7.10 (d, J=8.1, 1H), 6.93 (d, J=8.1, 1H), 4.21 
(bs, 1H), 3.19 – 3.14  (m, 2H), 2.81 – 2.77  (m,, 2H), 2.28 – 2.20 (m, 5H), 2.14 – 2.03 (m, 
2H). 13C NMR (100 MHz, CDCl3) δ 152.7, 129.0, 126.4, 125.9, 125.6, 123.2, 120.5, 
114.8, 58.6, 45.9, 34.3. HRMS (EI+) calcd. for [C12H15ClIN] (M+) 334.994; found 




1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.7 Hz, 2H), 4.28 – 
4.28 (m, 1H), 3.64 – 3.53 (m, 2H), 3.25 – 3.15 (m, 2H), 2.23 – 2.17 (m, 2H), 2.04 – 1.91 
(m, 2H). 13C NMR (100 MHz, CDCl3) δ 152.7, 129.0, 126.4, 125.9, 125.6, 123.2, 120.5, 
190 
114.8, 58.6, 45.9, 34.3. 19F NMR (376 MHz, CDCl3) δ -61.35. HRMS (EI+) calcd. for 




1H NMR (400 MHz, CDCl3) δ = 6.93 (d, J=9.0, 2H), 6.85 (d, J=8.9, 2H), 4.24 – 4.12 (m, 
1H), 3.79 (s, 3H), 3.46 – 3.34 (m, 2H), 3.00 – 2.90 (m, 2H), 2.22 (s, 2H), 2.12 – 2.00 (m, 
2H).  13C NMR (100 MHz, CDCl3) δ 153.9, 145.6, 118.8, 114.4, 57.1, 55.5, 49.1, 35.4.  
HRMS (EI+) calcd. for [C12H17ONCl] (MH+) 226.0993; found 226.0990. Colorless oil, 




1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 9.0 Hz, 2H), 6.87 (d, J = 9.0 Hz, 2H), 4.31 – 
4.26 (m, 1H), 3.69 – 3.57 (m, 2H), 3.32 – 3.26 (m, 2H), 2.21 – 2.14 (m, 2H), 2.00 – 1.92 
(m, 2H). 13C NMR (100 MHz, CDCl3) δ 152.7, 133.4, 119.8, 114.3, 100.0, 56.3, 44.9, 
34.1. HRMS (EI+) calcd. for [C12H14N2Cl] (MH+) 221.0840; found 221.0837. Colorless oil, 





1H NMR (400 MHz, CDCl3) δ = 7.11 (d, J=8.7, 2H), 6.90 (d, J=8.9, 2H), 4.22 (dt, J=11.7, 
3.8, 1H), 3.53 – 3.44 (m, 2H), 3.13 – 3.03 (m, 2H), 2.21 (dd, J=14.6, 11.6, 2H), 2.06 – 
1.96 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 149.7, 141.9, 124.2, 121.8, 119.2, 117.1, 
114.4, 112.8, 56.6, 47.3, 34.7.  19F NMR (376 MHz, CDCl3) δ = -58.32. HRMS (EI+) 





1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 9.4 Hz, 2H), 6.82 (d, J = 9.4 Hz, 2H), 4.32 (dq, 
J = 10.8, 3.7 Hz, 1H), 3.78 – 3.65 (m, 2H), 3.40 (ddd, J = 11.5, 7.3, 3.6 Hz, 2H), 2.26 – 
2.11 (m, 2H), 2.01 – 1.93 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 154.4, 138.4, 126.1, 
112.9, 56.3, 44.9, 34.3. HRMS (EI+) calcd. for [C11H13ClN2 O2] (M+) 240.0669; found 





1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 7.9 Hz, 1H), 7.51 (t, J = 7.7 Hz, 1H), 7.37 (d, J 
= 8.1 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 4.23 (bs, 1H), 3.21 – 3.02 (m, 2H), 2.81 (ddd, J = 
11.2, 7.7, 3.2 Hz, 2H), 2.21 (ddd, J = 13.5, 6.9, 3.4 Hz, 2H), 2.09 – 1.97 (m, 2H). 13C 
NMR (100 MHz, CDCl3) δ 152.8, 132.9, 128.6, 127.3, 127.0, 125.5, 125.0, 124.2, 122.8, 
120.1, 57.4, 51.4, 35.9. 19F NMR (376 MHz, CDCl3) δ -60.5, -62.21 (side product). 
HRMS (EI+) calcd. for [C12H14NClF3] (MH+) 264.0761; found 264.0758. Colorless oil, 




1H NMR (400 MHz, CDCl3) δ 7.32 –7.21 (m, 3H), 4.28 (tt, J=7.4, 3.7, 1H), 3.64 – 3.55 (m, 
2H), 3.29 – 3.19 (m, 2H), 2.22 (ddt, J=14.3, 7.4, 3.6, 2H), 2.06 – 1.96 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ 151.3, 132.8, 132.5, 132.2, 131.8, 127.5, 124.8, 122.1, 119.4, 115.0, 
112.0, 56.0, 46.0, 34.3. 19F NMR (376 MHz, CDCl3) δ = -63.10.  HRMS (EI+) calcd. for 





1H NMR (400 MHz, CDCl3) δ 7.35 (t, J = 8.0 Hz, 1H), 7.12 (s, 1H), 7.08 (d, J = 8.2 Hz, 
2H), 4.24 (tt, J = 7.8, 3.8 Hz, 1H), 3.60 – 3.48 (m, 2H), 3.20 – 3.08 (m, 2H), 2.29 – 2.15 
(m, 2H), 2.07 – 1.94 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 151.1, 131.9, 131.6, 131.3, 
130.9, 129.6, 125.6, 122.9, 119.2, 115.9, 114.6, 112.6, 56.6, 46.8, 34.7. 19F NMR (376 
MHz, CDCl3) δ  -62.83. HRMS (EI+) calcd. for [C12H14NClF3] (MH+) 264.0761; found 




1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 7.6 Hz, 2H), 7.43 (d, J = 8.6 Hz, 2H), 7.32 (t, J 
= 7.6 Hz, 2H), 7.19 (dd, J = 14.7, 7.2 Hz, 1H), 6.91 (d, J = 8.6 Hz, 2H), 4.16 – 4.10  (m, 
1H), 3.51 – 3.43 (m, 2H), 3.08 – 2.97 (m, 2H), 2.19 – 2.08 (m, 2H), 1.99 – 1.87 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 150.1, 140.7, 132.2, 128.6, 127.7, 126.4, 126.4, 116.5, 
57.0, 47.3, 34.8. HRMS (EI+) calcd. for [C17H19NCl] (MH+) 272.1201; found 272.1200. 





1H NMR (400 MHz, CDCl3) δ 7.65 – 7.60 (m, 2H), 7.42 (dd, J=10.5, 4.7, 2H), 7.34 – 7.24 
(m, 3H), 7.08 (ddd, J=11.9, 9.2, 4.6, 2H), 4.13 – 3.97 (m, 1H), 3.18 – 3.07 (m, 2H), 2.70 
(ddd, J=11.8, 8.8, 2.9, 2H), 2.01 – 1.93 (m, 2H), 1.86 – 1.71 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 150.2, 141.0, 135.1, 131.3, 128.6, 128.1, 126.7, 122.7, 118.5, 57.3, 49.4, 35.6. 
HRMS (EI+) calcd. for [C17H19NCl] (MH+) 272.1201; found 272.1199. Colorless oil, 114.1 




1H NMR (400 MHz, CDCl3) δ 7.87 (d, J=9.0, 2H), 6.87 (d, J=9.0, 2H), 4.28 (tt, J=7.6, 3.8, 
1H), 3.68 (ddd, J=12.8, 7.3, 3.6, 2H), 3.29 (ddd, J=13.2, 7.8, 3.5, 2H), 2.52 (s, 3H), 2.05-
1.95 (m, 2H), 1.96 (dtd, J=11.3, 7.7, 3.6, 2H). 13C NMR (100 MHz, CDCl3) δ 196.4, 153.6, 
130.4, 127.5, 113.6, 56.7, 45.3, 34.4, 26.1.  HRMS (EI+) calcd. for [C13H17ONCl] (MH+) 





1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 7.5 Hz, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.48 (t, J 
= 7.6 Hz, 2H), 7.39 (s, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.18 (dd, J = 14.1, 7.7 Hz, 2H), 4.23 
(tt, J = 7.8, 3.8 Hz, 1H), 3.61 – 3.51 (m, 2H), 3.19 – 3.09 (m, 2H), 2.21 (bs, 2H), 2.07 – 
1.96 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 196.9, 150.8, 138.4, 137.6, 132.3, 130.0, 
128.8, 128.1, 121.7, 120.4, 117.1, 56.7, 47.0, 34.7. HRMS (EI+) calcd. for [C18H19ONCl] 




1H NMR (400 MHz, CDCl3) δ 6.71 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 2.3 Hz, 1H), 6.37 (dd, 
J = 8.4, 2.4 Hz, 1H), 5.90 (s, 2H), 4.17 (td, J = 8.0, 4.0 Hz, 1H), 3.40 – 3.27 (m, 2H), 2.92 
(ddd, J = 12.0, 8.4, 3.4 Hz, 2H), 2.20 (dd, J = 16.4, 3.5 Hz, 2H), 2.08 – 1.94 (m, 2H). 13C 
NMR (100 MHz, CDCl3) δ 110.0, 109.7, 108.1, 100.9, 100.5, 84.4, 57.0, 49.2, 35.3. 
HRMS (EI+) calcd. for [C12H14O2NCl] (MH+) 239.0713; found 239.0707. Yellow liquid, 
81.3 mg, 68 % yield. 
 
methyl 3-(4-chloropiperidin-1-yl)thiophene-2-carboxylate (5-2w) 
196 
 
1H NMR (500 MHz, CDCl3) δ 7.38 (d, J = 5.4 Hz, 1H), 6.84 (d, J = 5.4 Hz, 1H), 4.37 – 
4.19 (m, 1H), 3.84 (s, 3H), 3.57 – 3.45 (m, 2H), 3.23 – 3.11 (m, 2H), 2.28 (ddd, J = 13.9, 
7.4, 3.9 Hz, 2H), 2.12 – 1.98 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 162.1, 157.6, 156.7, 
131.1, 121.0, 56.9, 51.6, 49.8, 35.2. HRMS (EI+) calcd. for [C18H19ONCl] (MH+) 
260.0434; found 264.0431. Pale yellow oil, 80.3 mg, 62 % yield. 
 
2-chloro-5-(4-chloropiperidin-1-yl)pyridine (5-2x) 
                                                                  
1H NMR (400 MHz, CDCl3) δ  8.15 – 8.03 (m, 1H), 7.41 (dd, J = 9.0, 2.7 Hz, 1H), 6.61 (d, 
J = 9.0 Hz, 1H), 4.27 (tt, J = 7.8, 3.8 Hz, 1H), 3.87 (ddd, J = 13.0, 7.1, 3.7 Hz, 2H), 3.41 
(ddd, J = 13.3, 8.1, 3.5 Hz, 2H), 2.20 – 2.08 (m, 2H), 1.96 – 1.82 (m, 2H). 13C NMR (100 
MHz, CDCl3) δ 157.3, 146.3, 137.2, 120.0, 107.8, 57.2, 43.2, 34.4. HRMS (EI+) calcd. 





1H NMR (400 MHz, CDCl3) δ  8.07 (d, J=1.5, 1H), 7.31 (s, 1H), 7.25 – 7.19 (m, 1H), 4.29 
(tt, J=7.5, 3.8, 1H), 3.58 – 3.47 (m, 2H), 3.23 – 3.12 (m, 2H), 2.26 (ddt, J=14.2, 7.3, 3.6, 
2H), 2.11 – 2.00 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 146.0, 141.3, 137.9, 126.2, 
124.0, 56.2, 46.5, 34.4. HRMS (EI+) calcd. for [C10 H12Cl2N2] (M+) 230.0382; found 




1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.88 (s, 1H), 4.34 – 4.28 (m, 1H), 3.89 – 3.81 
(m, 2H), 3.55 – 3.47 (m, 2H), 2.18 – 2.11 (m, 2H), 1.97 – 1.89 (m, 2H). 13C NMR (100 
MHz, CDCl3) δ 153.4, 141.0, 136.0, 129.2, 56.6, 42.4, 34.2. HRMS (EI+) calcd. for 





1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.16 – 
4.09 (m, 1H), 3.21 – 3.07 (m, 4H), 2.44 (s, 3H), 2.16 – 2.09 (m, 2H), 1.98 – 1.89 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 143.5, 132.8, 129.6, 127.4, 55.2, 42.7, 33.8, 21.4. HRMS 





1H NMR (400 MHz, (CDCl3) δ 7.60 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 4.07 – 
3.97 (m, 1H), 3.78 (s, 3H), 3.11 – 3.05 (m, 2H), 3.03 – 2.95 (m, 2H), 2.10 – 1.97 (m, 2H), 
1.88 – 1.80 (m, 2H).. 13C NMR (100 MHz, (CDCl3) δ 162.9, 129.5, 127.6, 114.1, 55.5, 
55.2, 42.7, 33.9. HRMS (EI+) calcd. for [C12H17O3NClS] (MH+) 290.0612; found 290.0610. 




1H NMR (400 MHz, CD3Cl3) 7.68 (d, J = 8.6, 2H), 7.62 (d, J = 8.6, 2H), 4.17 – 4.13 (m, 
1H), 3.15 (t, J = 5.4 Hz, 4H), 2.17 – 2.10 (m, 2H), 1.97 – 1.91 (m, 2H).13C NMR (100 
MHz, CDCl3) δ 135.4, 132.6, 129.2, 128.2, 55.2, 42.9, 34.1. HRMS (EI+) calcd. for 
199 





1H NMR (500 MHz, CDCl3) δ 4.01 (bs, 1H), 2.71 (bs, 2H), 2.13 (dd, J = 6.6, 4.4 Hz, 5H), 
1.98 – 1.81 (m, 3H), 1.44 (bs, 2H), 1.29 – 1.23 (m, 7H), 0.88 (dt, J = 14.9, 7.1 Hz, 7H). 
13C NMR (126 MHz, CDCl3) δ 62.7, 58.0, 52.2, 36.5, 35.8, 31.5, 28.9, 24.7, 23.1, 14.1, 
10.8. HRMS (EI+) calcd. for [C13H26ClN] (M+) 231.1756; found 231.1751. Colorless oil, 




1H NMR (400 MHz, CDCl3) δ 7.32 – 7.10 (m, 5H), 4.01 (s, 1H), 2.78 – 2.72 (m, 4H), 2.54 
(dd, J=9.7, 6.5, 2H), 2.27 (bs, 2H), 2.07 (d, J=12.4, 2H), 1.94 – 1.80 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ 140.2, 128.6, 128.3, 125.9, 60.3, 57.3, 51.2, 35.5, 33.7. HRMS (EI+) 





1H NMR (400 MHz, CDCl3) δ 7.11 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 4.12 – 
4.00 (m, 1H), 3.79 (s, 3H), 2.88 – 2.79 (m, 2H), 2.78 – 2.67 (m, 3H), 2.61 – 2.52 (m, 2H), 
2.38 – 2.25 (m, 2H), 2.18 – 2.08 (m, 2H), 2.00 – 1.86 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 158.0, 132.3, 129.6, 113.8, 60.6, 57.4, 55.3, 51.3, 35.6, 32.9. HRMS (EI+) 





1H NMR (400 MHz, CDCl3) δ 7.43 – 7.12 (m, 5H), 4.03 (bs, 1H), 3.49 (bs, 2H), 2.80 – 
2.67 (m, 2H), 2.23 (s, 2H), 2.13 – 2.02 (m, 2H), 1.96 – 1.84 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 138.3, 129.0, 128.2, 127.0, 62.8, 57.5, 51.3, 35.6. HRMS (EI+) calcd. for 





1H NMR (400 MHz, CDCl3) δ 7.38 – 7.21 (m, 5H), 3.98 (bs, 1H), 3.44 (q, J=6.7, 1H), 
2.86 (bs, 1H), 2.78 – 2.66 (m, 1H), 2.29 – 2.12 (m, 2H), 2.14 – 1.99 (m, 2H), 1.97 – 1.80 
(m, 2H), 1.37 (d, J=6.7, 3H). 13C NMR (100 MHz, CDCl3) δ 143.8, 128.2, 127.5, 126.9, 
64.4, 57.8, 48.6, 35.9, 19.4. HRMS (EI+) calcd. for [C13 H19NCl] (MH+) 224.1201; found 




1H NMR (400 MHz, CDCl3) δ 7.32 – 7.22 (m, 2H), 6.96 (d, J = 8.6 Hz, 2H), 6.85 (t, J = 
7.0 Hz, 1H), 3.51 (d, J = 12.8 Hz, 2H), 3.25 – 3.12 (m, 2H), 1.95 (ddd, J = 22.6, 18.0, 8.3 
Hz, 4H), 1.68 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 151.1, 129.1, 119.5, 116.4, 69.5, 
46.0, 40.3, 33.2. HRMS (EI+) calcd. for [C12H17NCl] (MH+) 210.1044; found 210.1040. 




1H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 7.9 Hz, 2H), 6.93 (d, J = 7.9 Hz, 2H), 6.88 (t, J 
= 7.3 Hz, 1H), 3.45 – 3.28 (m, 4H), 2.68 (ddd, J = 13.7, 7.1, 3.7 Hz, 2H), 2.55 (ddd, J = 
13.7, 7.0, 3.7 Hz, 2H). 13C NMR (100 MHz CDCl3) δ 150.2, 129.1, 120.0, 116.4, 78.9, 
202 
47.5, 46.4. HRMS (EI+) calcd. for [C11H13BrClN] (M+) 272.9917; found 274.9890. 




1H NMR (500 MHz, CDCl3) δ 7.23 (d, J = 8.1 Hz, 2H), 6.91 (d, J = 8.1 Hz, 2H), 6.79 (t, J 
= 7.2 Hz, 1H), 3.70 – 3.60 (m, 3H), 2.79 (td, J = 12.6, 3.0 Hz, 1H), 2.45 – 2.38 (m, 1H), 
2.23 (td, J = 12.1, 6.4 Hz, 1H), 2.10 (td, J = 12.8, 4.5 Hz, 1H), 1.92 – 1.84 (m, 2H), 1.79 
(d, J = 10.7 Hz, 1H), 1.61 – 1.54 (m, 1H), 1.35 (d, J = 11.2 Hz, 1H), 1.08 (s, 3H), 1.01 (s, 
3H), 0.92 (dt, J = 13.0, 4.4 Hz, 1H).  13C NMR (126 MHz, CDCl3) δ 151.1, 129.0, 118.9, 
116.3, 77.7, 55.2, 51.8, 47.5, 47.3, 39.4, 34.8, 30.5, 30.4, 29.9, 27.7, 23.2. HRMS (EI+) 




1H NMR (400 MHz, CDCl3) Major (anti-) diastereomer: δ 7.31 – 7.22 (m, 2H), 6.96 – 
6.90 (m, 2H), 6.86 (t, J = 7.3 Hz, 1H), 3.73 – 3.57 (m, 3H), 2.80 (td, J = 12.5, 2.7 Hz, 1H), 
2.50 (dd, J = 12.9, 10.6 Hz, 1H), 2.31 – 2.21 (m, 1H), 2.14 – 1.95 (m, 2H), 1.14 (d, J = 
6.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 150.7, 129.1, 119.7, 116.5, 64.7, 56.4, 49.4, 
203 
39.5, 35.8, 16.9. HRMS (EI+) calcd. for [C12H17NCl] (MH+) 210.1044; found 210.1042. 
Colorless oil, 68.1 mg, 65% yield. 
 
 





































































































































































































































































































































3.4.6 X-ray data for 5-2n 
 
  Table 5.1.  Crystal data and structure refinement for 5-2n. 
Identification code  5-2n 
Empirical formula  C11 H13 Cl N2 O2 
Formula weight  240.68 
Temperature  101.95(10) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P nma 
Unit cell dimensions a = 17.2486(2) Å = 90°. 
 b = 10.17867(17) Å = 90°. 
 c = 6.17147(11) Å  = 90°. 
Volume 1083.51(3) Å3 
Z 4 
Density (calculated) 1.475 Mg/m3 
Absorption coefficient 0.338 mm-1 
F(000) 504 
Crystal color, habit yellow plate 
Crystal size 0.39 x 0.38 x 0.05 mm3 
Theta range for data collection 3.51 to 33.12°. 
Index ranges -26<=h<=25, -15<=k<=15, -9<=l<=9 
Reflections collected 26127 
Independent reflections 2160 [R(int) = 0.0265] 
Completeness to theta = 33.12° 99.9 %  
Absorption correction SCALE 3 ABSPACK 
Max. and min. transmission 1.000 and 0.906 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2160 / 0 / 102 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0320, wR2 = 0.0722 
R indices (all data) R1 = 0.0364, wR2 = 0.0746 
Largest diff. peak and hole 0.489 and -0.344 e.Å-3 
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 Table 5.2.  Atomic coordinates and equivalent isotropic displacement parameters (Å2) for 5-2n.   
                   U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Cl(1) 0.3167(1) 0.2500 0.6844(1) 0.033(1) 
O(1) -0.466(1) 0.1437(1) -0.5484(1) 0.025(1) 
N(1) 0.1383(1) 0.2500 0.3151(2) 0.018(1) 
N(2) -0.272(1) 0.2500 -0.4688(2) 0.018(1) 
C(1) 0.3040(1) 0.2500 0.3903(2) 0.025(1) 
C(2) 0.2604(1) 0.1265(1) 0.3244(2) 0.024(1) 
C(3) 0.1761(1) 0.1318(1) 0.3992(2) 0.021(1) 
C(4) 0.1019(1) 0.2500 0.1168(2) 0.015(1) 
C(5) 0.0810(1) 0.1313(1) 0.0126(1) 0.017(1) 
C(6) 0.0394(1) 0.1313(1) -0.1790(1) 0.017(1) 
C(7) 0.0182(1) 0.2500 -0.2727(2) 0.015(1) 
________________________________________________________________________________ 
287 
 Table 5.3.   Bond lengths [Å] and angles [°] for 5-2n. 
_____________________________________________________  
Cl(1)-C(1)  1.8285(14) 
O(1)-N(2)  1.2347(8) 
N(1)-C(4)  1.3753(15) 
N(1)-C(3)#1  1.4632(11) 
N(1)-C(3)  1.4632(11) 
N(2)-O(1)#1  1.2347(8) 
N(2)-C(7)  1.4417(15) 
C(1)-C(2)#1  1.5206(13) 
C(1)-C(2)  1.5206(13) 
C(1)-H(1)  0.972(19) 
C(2)-C(3)  1.5270(13) 
C(2)-H(2A)  0.941(13) 
C(2)-H(2B)  0.977(13) 
C(3)-H(3A)  0.955(13) 
C(3)-H(3B)  0.998(13) 
C(4)-C(5)  1.4155(10) 
C(4)-C(5)#1  1.4155(10) 
C(5)-C(6)  1.3824(11) 
C(5)-H(5)  0.936(12) 
C(6)-C(7)  1.3886(10) 
C(6)-H(6)  0.935(12) 








































Symmetry transformations used to generate equivalent atoms:  #1 x,-y+1/2,z       
 
 
Table 5.4.   Anisotropic displacement parameters (Å2) for 5-2n.  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Cl(1) 0.022(1)  0.050(1) 0.025(1)  0.000 -0.008(1)  0.000 
O(1) 0.028(1)  0.022(1) 0.024(1)  -0.007(1) -0.006(1)  0.000(1) 
N(1) 0.018(1)  0.020(1) 0.017(1)  0.000 -0.002(1)  0.000 
N(2) 0.017(1)  0.020(1) 0.016(1)  0.000 0.000(1)  0.000 
C(1) 0.017(1)  0.037(1) 0.021(1)  0.000 0.003(1)  0.000 
C(2) 0.023(1)  0.027(1) 0.021(1)  0.001(1) 0.001(1)  0.007(1) 
C(3) 0.020(1)  0.023(1) 0.019(1)  0.005(1) -0.003(1)  -0.001(1) 
C(4) 0.013(1)  0.017(1) 0.015(1)  0.000 0.001(1)  0.000 
C(5) 0.019(1)  0.014(1) 0.018(1)  0.001(1) 0.000(1)  0.001(1) 
C(6) 0.018(1)  0.015(1) 0.017(1)  -0.001(1) 0.001(1)  -0.001(1) 





Table 5.5.   Hydrogen coordinates and isotropic displacement parameters (Å2) for 5-2n. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 0.3564(11) 0.2500 0.3320(30) 0.030 
H(2A) 0.2846(7) 0.0508(13) 0.3800(20) 0.028 
H(2B) 0.2619(8) 0.01218(13) 0.1660(20) 0.028 
H(3A) 0.1485(7) 0.0541(13) 0.3590(20) 0.025 
H(3B) 0.1742(7) 0.1354(13) 0.5610(20) 0.025 
H(5) 0.0941(7) 0.0499(12) 0.0727(19) 0.021 
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          APPENDIX A: LIGAND EFFECTS IN THE GOLD 
         CATALYZED HYDRATION OF ALKYNES  
Background 
The hydration of alkynes is a straightforward and atom-economical method to prepare 
carbonyl compounds.135,136 Hg,137 Fe,138 Ru,139 Pd,140 Ir,141 Pt,142 Ag,143 Cu144 based 
catalysts as well as other system145 have been developed for this purpose. Among them, 
gold catalysts appeared to be especially efficient.136, 146 State of the art methods include 
Nolan and coworkers’ [IPr-AuI]-catalyzed alkyne hydration at ppm level gold catalyst 
loadings (Scheme 12a), although high temperatures (e.g. 120 oC) are needed to achieve 
high efficacy.136 Another example is Corma and coworkers’ isolable SPhos based gold(I) 
complex catalyzed alkyne hydration at room temperature without acidic promoters,147 
although a relatively high gold catalyst loading (0.5-5%) was needed (Scheme 12b). 
Scheme 12. State of the art methods for gold catalyzed hydration of alkynes. 
 
Low gold catalyst loading is essential for larger scale synthesis and the use of relative 
low temperatures is important for the synthesis of complex target molecules, which 
usually contain sensitive functional groups. Our goal was to find a gold hydration catalyst 
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with a suitable ligand that is efficient at low loading (ppm level) and at low temperature 
(e.g., room temperature). 
Results and discussion 
Ligands are known to play a crucial role in modulating the reactivity of cationic gold 
catalysts.86b, 148 To study the effects of ligands we used the hydration of 1-octyne A-1a 
as model reaction (Figure 12). The ligands used by Nolan (IPr, A-L1) and Corma 
(SPhos, A-L5) were indeed efficient, both A-L1 and A-L5 catalytic systems 
accomplished the hydration of alkyne A-1 at room temperature in 24 h. To our surprise, 
most ligands performed similarly, even the very electron poor ligand P(OPh)3 was an 
equally good ligand. In contrast to many gold catalyzed reactions, like hydroamination,148 
the electronic effect of the ligand played only a small role in the kinetics of alkyne 
hydration.149 For example, an electron poor ligand (A-L8) behaved very similarly to an 
electron rich ligand (A-L5). Conversely, the steric effects of ligands played a crucial role 
in alkyne hydration; for example, a bulkier ligand (t-BuX-Phos, A-L3) led to a faster 
reaction rate compared to JohnPhos (A-L2). We found that the most sterically 
demanding Buchwald ligand A-L4 (Me3(OMe)tBuXPhos, it is a mixture of two 
regioisomers)150 was the best for this reaction. It should be note that this reaction is not a 
pure water addition process, it may involve a combination of hydroalkoxylation (methanol 
addition) and the subsequent hydrolysis of the enol ether/acetal by water in situ. A 
rationale for the role of steric hindrance in the performance of these ligands is not yet 
clear. It has been reported that the high affinity of gold for both gold and silver, causes 
various Au-Ag,151,152 Au-Au153 intermediates to be formed in gold catalyzed reactions 
(Figure 13); these intermediates often behave as off-cycle species.153 
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Figure 12. Screening for the optimal ligand for hydration of alkyne 1a. 
 


























It is likely that sterically hindered ligands discourage the formation of these off-cycle gold 
intermediates, which in turn lead to the high turnover of gold catalysts.  
Figure 13. Au-Ag, Au-Au intermediates in catalytic cycle. 
 
With the best catalytic system (A-L4-Au-OTf) for alkyne hydration in hand, we explored 
the substrate scope (Table 13). The A-L4-Au-OTf system was able to catalyze the 
hydration of most alkynes at low catalyst loading (0.02%) and relatively low temperature 
(80oC). Both terminal and internal alkynes worked well and many common functional 
groups such as alcohol (Table 13, entry 12), ester (Table 13, entries 13, 15), and 
carboxylic acid154 (Table 13, entry 14) were tolerated.  
In many gold catalyzed reactions, the use of acidic promoters has been shown to ease 
the reaction conditions.155 When we used acidic promoters with our optimized catalytic 
system we found that the hydration of 1-octyne took place under both, lower catalyst 
loading and reduced reaction temperature (Table 14). It should be noted that without an 
acid promoter, A-L4-Au-OTf (0.1%) was not able to complete the reaction at room 
temperature (Table 14, entry 1). Most acids sped up the reaction but strong acids such 
as H3PW12O40 and TfOH performed best (Table 14, entries 6, 9). Complete conversions 














Table 14. Hydration of alkynes in the presence of acid promoter 
 
entry [Au] additive time conversion 
1 0.1% None 24 h < 5% 
2 0.1% Cu(OTf)2 (0.2%) 24 h 15% 
3 0.1% Eu(OTf)3 (0.2%) 24 h < 5% 
4 0.1% H3PW12O40 (0.2%) 24 h >99% 
5 0.01% H3PW12O40 (0.15%) 24 h >99% 
6 0.01% H3PW12O40 (0.15%) 12 h >99% 
7 0.01% HNTf2 (0.15%) 21 h 69% 
8 0.01% HOTf (0.15%) 21 h 93% 
9 0.01% HOTf (0.45%) 21 h >99% 
10 - HOTf (0.45%) 24 h 0% 
catalyst loading (0.01%) at room temperature. An acid alone cannot catalyze the reaction at room temperature (Table 14, 
entry 10). 
We examined the substrate scope for our L4-Au-OTf/acid system (Table 15). For most 
terminal alkynes, the reaction proceeded very well at very low gold catalyst loading 
(0.01%) at room temperature (Table 15, entries 1-9). For internal alkynes, a higher 
temperature and catalyst loading (0.03%) was needed to achieve high conversion (Table 
15, entries 10-11). 
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In summary, a gold catalyst containing a highly sterically hindered and commercially 
available phosphine ligand (A-L4) was able to catalyze the alkyne hydration of a wide 




General Methods and Materials                                                                             
All commercial reagents and solvents were obtained from the commercial provider and 
used without further purification.  1H and 13C NMR spectra were recorded at 500 MHz 
and 126 MHz (or 400 MHz and 101 MHz) respectively using CDCl3 as a solvent. The 
chemical shifts are reported in δ (ppm) values (1H and 13C NMR relative to CHCl3, δ 7.26 
ppm for 1H NMR and δ 77.0 ppm for 13C NMR), multiplicities are indicated by s (singlet), 
d (doublet), t (triplet), q (quartet), p (pentet), h (hextet), m (multiplet) and br (broad). 
Coupling constants (J) are reported in Hertz (Hz). The product formation was monitored 
by 1H NMR using aliquots containing the solvent mixture. 
Synthesis of gold complexes (L-AuCl)  
All gold complexes (L-AuCl) were synthesized using a slightly modified version of a 
literature method.91, 156These complexes were prepared via either one of the following 
general procedures:  
Method 1: Sodium tetrachloroaurate(III) dihydrate (1 mmol) was dissolved in water, and 
the orange solution was cooled in ice. To this solution, 2,2’-thiodiethanol (3 mmol) was 
slowly added (ca. 10 min) with stirring. After stirring at 0oC for another 30 min, a solution 
of the phosphine ligand (1 mmol) in EtOH (if the ligand could not be dissolved, more 
EtOH was used) was added dropwise to yield a white solid. The solid was filtered off, 
washed with water followed by EtOH, and ultimately dried in vacuum to obtain the 
complex quantitatively. 
Method 2: To a vial Chloro(dimethylsulfide)gold(I) (1 mmol) was dissolved in 
dichloromethane and cooled in an ice bath. A solution of phosphine ligand (1 mmol) in 
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dichloromethane was added dropwise, and the resulting solution was allowed to warm to 
room temperature and stirred at room temperature for 3 h. After TLC indicated complete 
consumption of the starting material, the reaction solution was concentrated to dryness 
in the rotovap, and the gold complex product was further dried under high vacuum to 
yield the complex quantitatively. 
Typical procedure for the acid free hydration (condition A): A glass vial equipped with a 
screw cap and a stir bar was charged with 1-octyne A-1a (112 mg, 150 µL, 1 mmol) 
dissolved in a mixture of MeOH (0.3 mL) and water (36 µL, 2 mmol). A stock solution of 
AgOTf (0.01 M in methanol, 30 µL, 0.0003 mmol) and a stock solution of A-L4-Au-Cl 
(0.01 M in methanol, 20 µL, 0.0002 mmol) were introduced to the reaction mixture. The 
reaction was stirred at 80 oC and the progress of reaction was monitored by GCMS or 
1H-NMR. Upon completion, reaction mixture was filtered through a celite plug, dried over 
anhydrous Na2SO4, filtered and solvent evaporated. The crude product was purified by 
silica gel column chromatography with EtOAc: Hex (1:5) as eluent.  
Typical procedure for acid co-catalyzed hydration (condition B): A glass vial 
equipped with a screw cap and a stir bar was charged with 1-octyne A-1a (112 mg, 150 
µL, 1 mmol) dissolved in 0.3 mL MeOH/water (25:1) mixture. A stock solution of acid 
promoter TfOH (0.01 M in methanol, 450 µL, 0.0045 mmol), a stock solution of AgOTf 
(0.01 M in methanol, 15 µL, 0.00015 mmol) and a stock solution of A-L4-Au-Cl (0.01 M 
in methanol, 10 µL, 0.0001 mmol) were introduced to the reaction mixture. The reaction 
mixture was stirred at room temperature and the progress of reaction was monitored by 
GCMS and 1H NMR. Upon completion, the reaction mixture was quenched with 
saturated bicarbonate (1 mL) and extracted with EtOAc (2 X 1 mL). The organics are 
dried over anhydrous Na2SO4, filtered and solvent evaporated using a rotoevaporator. 
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The crude product was subjected to silica gel column chromatography with EtOAc: Hex 
(1:5) as eluent. 
1H NMR, 13C NMR and 31P NMR data of L4-AuCl and 1H NMR data 
hydration products 
The hydration products (ketones 2): 2a (CAS#111-13-7)157, 2b (CAS #591-78-6)158, 2c 
(CAS#13505-34-5)159 , 2c’(1193-18-6)160, 2d (2550-26-7)161, 2e (CAS#932-66-1)162, 2f 
(CAS#403-42-9)158, 2g (CAS#100-06-1)158, 2h (CAS#1009-61-6)158, 2i (CAS#577-16-
2)163, 2j (cas # 589-63-9)164, 2k (cas # 693-54-9165, 928-80-3166), 2l167, 2m (cas #19275-
80-3)168, 2n (cas # 13984-50-4)169, 2o (cas #24889-15-4)170, 2p (CAS#451-40-1)158, 2q 
(cas # 1123-27-9)171 are commercially available and reported compounds and their 
spectroscopic data agree well with the reported literature. 
A-L4-AuCl: White solid; 
Major isomer: 1H NMR (400 MHz, CDCl3) δ ppm 7.05 (s, 2 H), 3.79 (s, 3 H), 2.99 (m, 1 
H), 2.62 (s, 3 H), 2.34 - 2.47 (m, 2 H), 2.23 (s, 3 H), 1.55-1.57 (m, 21 H), 1.29-1.31 (d, 12 
H), 0.89-0.90 (d, 6 H) 
Minor isomer: 1H NMR (400 MHz, CDCl3) δppm 7.05 (s, 2 H), 3.68 (s, 3 H), 2.99 (m, 
1H), 2.59 (s, 3 H), 2.34 - 2.47 (m, 2 H), 2.23 (s, 3 H), 1.49-1.53 (m, 21 H), 1.37-1.39 (d, 
12 H), 0.85-0.87 (d, 6 H). 13C NMR (CDCl3, 100 MHz) δ 13.5, 17.2, 21.5, 23.7, 25.2, 
30.3, 33.3, 38.7, 41.7, 59.4, 59.7, 68.1, 122.6, 126.3, 129.9, 133.1, 136.5, 139.5, 144.4, 
148.6, 156.4, 156.5, 159.5, 159.6. 31P NMR (162 MHz, CDCl3) δ 75.96, 75.81  
2-octanone (A-2a) 157 
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Colorless oil, 116.5 mg, 91%. 1H NMR (400 MHz, CDCl3) δ 2.41 (t, J = 7.5 Hz, 2H), 2.13 
(s, 3H), 1.55 (dd, J = 14.4, 7.2 Hz, 2H), 1.38 – 1.17 (m, 6H), 0.87 (t, J = 6.7 Hz, 3H).  
2-hexanone (A-2b) 158 
 
Colorless oil, 91.4 mg, 91%. 1H NMR (400 MHz, CDCl3) δ = 2.36 (t, J=7.5, 2H), 2.06 (s, 
3H), 1.52- 1.45 (m, 2H), 1.30 – 1.18 (m, 2H), 0.83 (t, J=7.3, 3H). 
Heptane-2,6-dione (A-2c) 159 
 
Colorless liquid, 113.2 mg, 89%. 1H NMR (400 MHz, CDCl3) δ = 2.42 (t, J=7.1, 4H), 2.08 
(s, 6H), 1.77 (p, J=7.1, 2H). 
3-methyl-2-cyclohexene-1-one (A-2c’) 159 
 
1H NMR (400 MHz, CDCl3) δ 6.01 – 5.60 (m, 1H), 2.41 – 2.19 (m, 4H), 2.08 – 1.81 (m, 
5H). yellow oil, 93.5 mg, 85% 
4-phenylbutan-2-one (A-2d) 161 
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Colorless oil, 130.8 mg, 88%. 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.15 (m, 2H), 2.90 (t, 
J = 7.6 Hz, 1H), 2.76 (t, J = 7.6 Hz, 1H), 2.14 (s, 1H).  
1-acetyl-1-cyclohexene (A-2e)162 
 
Light yellow oil, 114.8 mg, 92%. 1H NMR (400 MHz, CDCl3) δ 6.85 (t, J = 3.8 Hz, 1H), 
2.31 – 2.05 (m, 7H), 1.70 – 1.39 (m, 4H).  
1-(4-fluorophenyl)ethan-1-one (A-2f) 158 
 
Colorless oil, 107.8 mg, 78%. 1H NMR (400 MHz, CDCl3) δ 7.98 (dd, J = 8.3, 5.8 Hz, 
2H), 7.12 (d, J = 8.5 Hz, 2H), 2.58 (s, 3H).  
4’-methoxyacetophenone (A-2g) 158 
 
White solid, 142.3 mg, 95%. 1H NMR (400 MHz, CDCl3) δ 7.86 (d, J = 8.6 Hz, 2H), 6.85 
(d, J = 8.6 Hz, 2H), 3.78 (s, 3H), 2.47 (s, 3H).  
1,4-diacetylbenzene (A-2h) 158 
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White solid, 144.3, 89%. 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 4H), 2.65 (s, 6H).  
2-methylacetophenone (A-2i) 163 
 
Colorless oil, 117.5 mg, 88%. 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 11.0 Hz, 2H), 
7.44 – 7.29 (m, 2H), 2.59 (s, 3H), 2.41 (s, 3H).  
4-octanone (A-2j) 164 
 
Colorless oil, 106 mg, 82%.1H NMR (400 MHz, CDCl3) δ = 2.35 (td, J=7.3, 5.2, 4H), 1.55 
(dp, J=22.7, 7.5, 4H), 1.33 – 1.22 (m, 2H), 0.87 (td, J=7.4, 2.7, 6H). 
Mixture of 2- and 3-decanone (A-2k) 165,166 
 
Colorless oil, 148 mg, 95%. 1H NMR (400 MHz, CDCl3) δ = 2.43 – 2.32 (m, 4H), 2.10 (s, 
2-decanone, 3H), 1.53 (m,2- and 3-decanone mixture, 3H), 1.26 (m, 2- and 3-decanone 
mixture, 15H), 1.01 (t, J=7.3, methyl of 3-decanone, 1H), 0.84 (t, J=6.9,2- and 3-
decanone mixture, 5H). 
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1-hydroxy-3-octanone (A-2l) 167 
 
Clear liquid, 124 mg, 86%. 1H NMR (400 MHz, CDCl3) δ = 3.61 (s, 1H), 2.56 – 1.63 (m, 
6H), 1.58 – 1.42 (m, 2H), 1.33 – 1.20 (m, 2H), 0.91 – 0.82 (t, 3H). 
2-oxo-1-phenylpropyl acetate (A-2m) 168 
 
Colorless liquid, 181 mg, 93%. 1H NMR (400 MHz, CDCl3) δ 7.39 (m, 5H), 5.97 (s, 1H), 
2.18 (s, 3H), 2.10 (s, 3H).  
methyl-5-oxohexanoate (A-2n) 169 
 
Colorless liquid, 110 mg, 76%. 1H NMR (400 MHz, CDCl3) δ = 3.65 (s, 3H), 2.49 (t, 
J=7.2, 2H), 2.36 – 2.29 (m, 2H), 2.13 (s, 3H), 1.88 (p, J=7.2, 2H). 
Dimethyl-2-(2-oxopropyl) malonate (A-2o) 170 
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Colorless oil, 180.4 mg, 95%. 1H NMR (400 MHz, CDCl3) δ = 3.86 (t, J=7.1, 1H), 3.73 (s, 
6H), 3.05 (d, J=7.2, 2H), 2.18 (s, 3H). 
1,2-diphenylethan-1-one (A-2p) 158 
 
White solid, 165.9 mg, 84%. 1H NMR (400 MHz, CDCl3) δ 8.02 (dd, J = 5.3, 3.3 Hz, 2H), 
7.60 – 7.51 (m, 1H), 7.51 – 7.42 (m, 2H), 7.38 – 7.22 (m, 5H), 4.29 (s, 2H).  
1-acetylcyclohexanol (A-2q) 171 
 
Yellow oil, 95.2 mg, 67%. 1H NMR (400 MHz, CDCl3) δ 3.61 (s, 1H), 2.21 (s, 3H), 1.28-




































































































































































































We have developed HBr/DMPU and HCl/DMPU reagents which will serve a good 
alternative to existing of hydrogen bromide and chloride solutions. The advantages of 
these reagents lie in the ease of handling, high concentration and especially unique 
reactivities towards alkenyl and alkynyl systems. The HBr reagent has been used in the 
hydrobromination of alkenes and alkynes without competition reactions caused by 
rearrangement or solvolysis. It also served as an effective substitution to other bromides 
in bromination transformations.  
HCl/DMPU reagent presented us with the first efficient regioselective homogeneous 
gold-catalyzed hydrochlorination of unactivated alkynes. This overcame the traditional 
incompatibility between conventional cationic gold catalysts and chloride.  
It was also shown to promote the chlorothiolation of alkenes, a transformation that 
affords biologically and synthetically relevant β-chlorothiolated compounds, using 
common and easy to handle starting materials like DMSO and less expensive feedstock; 
alkenes. The procedure showed good functional group compatibility—both terminal and 
internal alkenes are suitable substrates—and is scalable.  
Finally, HCl/DMPU induces the formation of (thiomethyl)methyl carbenium ion from 
DMSO under mild conditions. Homoallylic amines react with this electrophile to generate 
4-chloropiperidines in good yields. The method is applicable to both aromatic and 
aliphatic amines. The use of HCl•DMPU as both non-nucleophilic base and chloride 
source constitutes an environmentally benign alternative for piperidine formation. With 
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this mildly generated carbosulfonium ion, this chemistry will be exploited to access a 
wide range of homologation cyclization reactions by altering reaction nucleophiles. 
Remarkably, the combination of HCl/DMPU and DMSO showed reactivity that is 
substrate dependent (Scheme 13). We observed that chloromethylthiolation is obtained 
for many (un)functionalized alkenes that do not have neighboring competing nucleophilic 
substituent. However, secondary amino alkenes will undergo a competitive cyclization 
reaction. For example, under similar conditions, secondary homoallylic amines afforded 
piperidines via iminium ion and a 6-exo-trig cyclization. 











DMPU: N, N'-Dimethylpropyleneurea 
DMSO: Dimethylsulfoxide 
dr: Diastereomeric ratio 
EI: Electrospray Ionization 
EtOAc: Ethyl acetate 
GC: Gas liquid chromatography 
h: Hour 
HBD: Hydrogen bond donor  
HBA: Hydrogen bond acceptor 
HCl: Hydrogen chloride 
HBr: Hydrogen bromide  
HF: Hydrogen fluoride  
HFIP: 1,1,1,3,3,3-Hexafluoro-2-propanol 
HOAc: Acetic acid 













NMR: Nuclear magnetic resonance spectroscopy 
o: Ortho 
p: Para 
ppm: Parts per million 
Py: Pyridine  
tert: Tertiary 
TMS: Trimethylsilyl 
TFA: Trifluoroacetic acid 
TfOH: Trifluoromethanesulfonic acid 
THF: Tetrahydrofuran 
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